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ABSTRACT
Equine bone marrow-derived mesenchymal stromal cells (MSCs) and adipose
tissue-derived stromal cells (ASCs) were compared for frequency within their respective
tissues, cell doubling characteristics and differentiation multipotential in culture based on
histochemical staining and compositional analysis. Equine MSCs and ASCs from young
adult horses were harvested and isolated from sternal bone marrow and supragluteal
subcutaneous adipose tissue, respectively, and grown up to passage 10 (P10) to determine
cell doubling characteristics. Limit dilution assays were performed on primary and
passaged (P2, P4) MSCs and ASCs to determine the frequency of colony forming units
with a fibroblastic phenotype (CFU-F), and the frequency of MSC differentiation into
adipocytes (CFU-Ad) and osteoblasts (CFU-Ob). Pellet cultures of MSCs and ASCs at
P2 were performed in chondrogenic media with or without transforming growth factor
(TGF-β3) and bone morphogenic protein (BMP-6). Collagen type II expression,
glycosaminoglycan and DNA content and pellet size were measured.
Primary MSCs doubled more slowly than subsequent MSC passages (DT = 4.9 ±
1.6 days compared to 1.4 ± 0.22 days). Doubling time of ASCs (2.1 ± 0.9 days) was
significantly slower than that of MSCs. Primary MSC frequency was 1 in 4,224 ± 3,265
nucleated BM cells while the frequency of ASC was 1 in 2.3 ± 0.4 nucleated stromal
vascular fraction cells. Primary and subcultured MSCs showed robust adipogenic and
osteogenic differentiation potential. MSC pellet cultures developed collagen type II
expression by Day 7 and hyaline matrix by Day 14. ASC pellets only exhibited mild
matrix or collagen formation under electron microscopic examination but showed no
immunohistochemical expression of collagen type II. MSC pellets supplemented with

xii

growth factors were larger (p <0.0033) and showed significant increases in GAG
concentration by Day 14 compared with all other pellets of both cell types (P<.0001).
The frequency, in vitro growth rate, and adipogenic and osteogenic differentiation
potential of young adult horses are similar to those documented for MSCs of other
species, whereas in vitro growth rate of ASCs differs from human ASCs. MSCs show
earlier osteogenesis compared with ASCs and more robust chondrogenesis in the
presence or absence of human recombinant TGFβ3 and BMP6.
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CHAPTER 1.
A REVIEW OF FUNDAMENTAL CONCEPTS IN STEM CELL BIOLOGY AND
MULTIPOTENTIAL CHARACTERISTCS AND MECHANISMS

1

1.1

Introduction to Stem Cell Biology: Definitions and Nomenclature
Stem cells are functional units responsible for generation of embryonic and adult tissue.1

The description of stem cells dates back to the 19th century, when Edmund Beecher Wilson
described the term as synonymous to a mitotically quiescent primordial germ cell.2 However, the
bulk of the research into the biology of mesenchymal stem cells started well over forty years ago
when Friedenstein and his coworkers showed that bone marrow derived cells could differentiate
into cell of mesenchymal origin, such as osteoblasts.3 During that time it was also shown that
demineralized bone or bone extracts were capable of causing cartilage or bone formation when
implanted either subcutaneously or intramuscularly.4-6 During the 1970s Caplan and his
coworkers demonstrated that mesenchymal cells from embryonic stage 24 chick limb buds could
be isolated and were able to differentiate in vitro into various mesenchymal tissues such as bone,
cartilage and muscle. Later it was found that exposure of these limb bud cells to demineralized
bone extracts would induce chondrogenic differentiation in a dose-dependent fashion, which lead
to the isolation of a demineralized bone crude extract with known dose dependent “chondrogenic
stimulating activity” (CSA). This protein was isolated, purified and characterized as a
heterodimer of what are now known as bone morphogenic proteins.5,7-10
These chick limb bud mesenchymal cells and the presence of CSA in demineralized bone
extracts as well as the aforementioned work by Urist and coworkers lead to the suspicion that
mesenchymal stromal cells also exist in adult tissues, which appeared consistent with the
enhanced efficiency of fracture repair when fresh bone marrow was used in large bone defects.5
Further support of this theory was work by Friedenstein11 and Owen12,13 that showed that bone
marrow-derived cells are capable of adhering to petri dishes and appeared to have osteogenic and
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adipogenic potential. This work set the stage for exploring the potential of adult mesenchymal
stromal cells (MSC) from varying tissue sources for the purpose of regenerative tissue repair.
1.1.1

Nomenclature of Mesenchymal Stromal Cells (MSCs)
For many years, the literature has published a confusing variety of different terminology

in its description of stem cells from different tissue sources.14 The property of bone marrowderived mesenchymal stromal cells to adhere to the plastic culture dish prompted the original
descriptive name of ‘plastic-adherent progenitor cells’.15 The literature often refers to the bone
marrow-derived stem cells with plastic adhering properties as mesenchymal stem cells, which
became popular through Arnold Caplan’s work and descriptions.16 However, it has been shown
that not all of these mesenchymal cells are in fact multipotent. Pittenger17 and his coworkers
showed that merely 70% of the unfractioned nucleated cell pool of marrow-derived cells was
capable of adipogenic, osteogenic and chondrogenic differentiation whereas the remainder of the
cells did not undergo chondrogenic differentiation. Hence it was concluded during the Annual
Meeting of the International Society for Cellular Therapy (ISCT) in 2000 that there is
insufficient evidence that all unfractioned fibroblast-like adhering cells have stem-like activity.18
It is generally accepted that unlike normal fibroblasts, such as those of dermal origin, those
isolated from bone marrow by plastic adherence have a multipotential biological properties but
are not a uniform population of cells. In fact, only a very small proportion of the marrow-derived
nucleated cell pool is capable of forming a colony-forming unit of fibroblasts (CFU-F)
demonstrating multipotential. Therefore, it has been proposed by Horwitz and coauthors to name
these cells multipotent mesenchymal stromal cells and suggest that only cells that have met
specified stem cell characteristics may be termed ‘mesenchymal stem cells’; this compromise
ascribes the popular ‘MSC’ acronym to both cell populations and maintains continuity within the
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literature.19 However, in the context of stromal cell descriptions from multiple tissue sources, the
term ‘mesenchymal stromal cell’ and its common acronym MSC, which merely refers to the
embryological origin of this cell type, can create confusion. If the cell is derived from bone
marrow it may be appropriately called BMSC, which is also a common acronym of these cells, in
order to distinguish the origin of this type of MSC from those of other origins.
Nomenclature from stromal cells of adipose tissue varies widely14 including descriptions
such as adipogenic reticular cell20, mesenchymal cell21, fibroblast, stromal cell and adiposederived adult stem cell (ADAS).22 A recent consensus reached at the Second Annual
International Fat Applied Technology Society meeting (IFATS, October 3-5, 2004, Pittsburgh,
PA) was to use the acronym ‘ASC’ for adipose-derived stromal cells23 or adipose-derived stem
cells.24
1.1.2

Stem Cell Definition and Self-renewal
Stem cells are clonogenic in nature capable of repeated cell division over many

generations without differentiation into a specific cell lineage. Genetic characteristics and
environmental cues such as cytokines, transcription factors, cell-to-cell or cell-to-matrix
interactions are believed to direct stem cells into a committed precursor cell lineage, which then
gives rise to mature progeny cells, which include nonrenewing progenitor cells and terminally
differentiated effector cells.25 Whether stem cells truly maintain absolute self-renewal potential
remains controversial. Marrow-derived MSCs have been shown to have a highly variable selfrenewal potential in culture.26,27 Friedenstein and his coworkers11 have shown that the cyclic
division known to occur in cell culture is not characteristic for cells in vivo. The cue for stem
cells to enter into the cell cycle appears to depend on serum growth factors and the addition of
increased concentration of growth factors such as the fibroblast growth factor-2 (FGF-2). This
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can cause expansion rates of more than 50 population or cell doublings (CD) compared with
control basal media cultures, which are usually bound by senescence to less than 50 CDs as
postulated by the Hayflick limit, which is discussed later.28,29
Another factor, which appears to effect the expansion rate a well as maintenance of
multipotentiality of human mesenchymal stromal cells, is lowering the seeding density of cells in
culture.27,30 Colter and coworkers showed dramatic differences in expansion rates when cells
were seeded at low compared with high densities.27 This work is supported by a recent report,
which showed that human bone marrow-derived MSCs seeded at 10 cells/cm2 expanded
approximately 500-fold within 12 days with a maximum cell doubling time of approximately 10
hours.31 When the same cells were seeded at 1,000 cells/cm2, they expanded only 30-fold, which
merely resulted in a 5-fold greater final cell count relative to the low density plating. The effect
of seeding density on the differentiation potential of cells was illustrated by Sekiya31 and his
coworkers who showed that after adipogenic induction of passage 3 human MSCs caused
significant reduction in absorbance levels for Oil Red O after isopropyl alcohol extraction when
cells were seeded at 1,000 cells/cm2 compared with those seeded at 50 cells/cm2.
The growth characteristics of MSCs depend on the species and the tissue origin.
Mesenchymal stromal cells derived from bone marrow show an initial lag phase of cell
proliferation in primary culture, which accelerates through a log phase and eventually plateaus.26
Cell doubling times of MSCs derived from bone marrow vary slightly among species, reported
as approximately every 48 hours for dogs32 and Rhesus Macaques33 whereas human postnatal
MSCs require approximately 24 hours.34 Furthermore, age-related decreases in growth rates have
been reported for intestinal stem cells using an irradiation model to simulate tissue aging in
mice35. Also differences between the in vitro culture conditions, including the concentrations of
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fetal bovine serum or the use of other serum substitutes such horse serum, have to be an
important consideration in the comparative assessment of cell growth characteristics as
determined in separate publications.
1.1.3

Stem Cell Replicative Control
Exciting new research in recent years has begun to elucidate the complex regulatory

control mechanisms that are involved in stem cell self-renewal. This process is believed to be
directed by cell intrinsic factors, epigenetic control, small RNA regulators, and cell-extrinsic
signals. Among the intrinsic transcription factors are orphan nuclear receptor TLX, polycomb
transcriptional repressor Bmi1, high-mobility-group DNA binding protein Sox2, and basic helixloop-helix Hes genes.36 Epigenetic control occurs through histone modifying enzymes and
chromatin remodeling proteins37 whereby histone modification can involve acetylation,
methylation, phosphorylation, ubiquitylation, sumolyation and ADP-ribosylation.38 Histone
acetylation has been most thoroughly examined and is regulated by histone acetylases (HATs)
and histone deactylases (HDACs). It has been shown that HDAC-mediated transcriptional
repression occurs through deacetylation of histone lysine residues and thereby restricts access of
transcription factors to their target genes. These processes are believed to be essential for the
maintenance, replication, and differentiation of neuronal stem cells.36
More recently the epigenetic control of self-renewal through histone methylation has
gained attention.39,40 The mechanism occurs through chromatin modifications of target genes
assuming a bivalent conformation facilitated by histone methylation, which is a dynamic process
regulated by methyl transferases and demethylases. Transcriptional control of self-renewal in
neuronal stem cells is closely related to the degree of lysine methylation leading to either mono-,
di-, or tri-methylated histones. Gene-specific ‘active’ or ‘repressive’ methylation complexes are
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then responsible for inducing replicative capacity through histone H3 lysine 4 (H3K4)
methylation, as seen in embryonic and neuronal cells. In contrast, repressive neuronal stem cell
genes carry histone H3 trimethyl K9 and histone H3 monomethyl K20 as well as histone H3K27,
of which the latter has also been reported for embryonic stem cells. The methylation status is
also linked to the differentiation capacity of stem cells whereby histone H3 trimethyl K20 has
been found abundantly in differentiation neuronal stem cells.36,37 These methylation
modifications are known to occur on target genes downstream to transcription factors Oct4,
Nanog, c-Myc, Klf4 and Sox2, which have been shown to be able to reprogram fibroblasts to a
pluripotent state and are therefore believed be important upstream regulators of the self-renewal
mechanism.37,41
Cellular processes including development, proliferation, and differentiation are also
controlled by small non-coding RNAs. A large family of the small non-coding RNAs recently
identified, are the miRNAs (micro-RNA) which are single-stranded fragments transcribed by
RNA polymerase II from miRNA genes (class II genes) and are known as negative regulators of
eukaryotic gene expression. Primary transcripts of miRNA, called pri-miRNAs, are converted
inside the nucleus to pre-miRNAs, which are hairpin precursors extruded into the cytoplasm
where they cleaved into mature miRNAs. These miRNAs are then complexed to an RNAinduced silencing complex (RISC) and presented to target mRNAs leading to their cleavage and
subsequent translational repression. It is believed that about one-third of all animal genes are
regulated by miRNAs and of all miRNAs thus far identified the majority (70%) appears to occur
in the brain, suggesting their importance in neuronal function.42-44
Cell-extrinsic signals occur through direct physical interactions between stem cells and
their biological niches are are soluble factors, which include Wnt, Notch and Sonic hedgehog
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(Shh).36 The Wnt/β-catenin signaling has been shown to be important in the proliferation
pathway of neuronal stem cells through downstream targets such as cyclin D1.45 Also Wnt3a and
Wnt5a have both been associated with stimulation of murine neuronal precursor cell proliferation
and differentiation.46 Notch signaling occurs by direct binding of a Notch ligand of one cell to
the Notch receptor of an adjacent cell, which facilitates the release of the intracellular Notch
domain and its translocation into the nucleus where it causes downstream effector expression
such as for genes of the Hes family.47,48 Notch is believed to maintain the self-renewable state of
stem cells.49 Finally, the sonic hedgehog (Shh) gene also is considered an important neural
progenitor cell mitogen in both the embryonic and adult brain maintaining cell proliferation
through mediation by the zinc finger-containing transcription factor Gli1.
Finally, it is believed that receptor tyrosine kinase signaling regulates stem cell
proliferation and self-renewal, controlled in part by extracellular ligands such as transforming
growth factor-alpha (TGFα), epidermal growth factor (EGF), and fibroblast growth factor
(FGF).50-53 It has been postulated that neuronal stem cells may be influenced by other
extracellular signals such as the Wnt, Notch and Shh derived from neighboring cell types, such
as astrocytes and neuroblasts, as well as ependymal and endothelial cells through interaction with
intrinsic signaling pathways such as the Wnt/-catenin-cyclin D1, Notch-hes1/5 and ShhGli1.36,54-56
1.1.4

Definition of Stem Cell Potency
Stem cells are categorized into classes of potency: (1) Totipotent cells such as those in a

fertilized egg are capable of forming an entire organism and are therefore able to give rise to any
embryonic and extra-embryonic cell type; (2) Pluripotent cells are capable of forming tissues of
all embryological origins such as endodermal, mesodermal and ectodermal tissues; whereas (3)
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multipotent cells, such as mesenchymal stromal cells of bone marrow17,57,58, are believed to be
restricted to the differentiation of one or more cell types within a single embryological germ
layer, and therefore limited to formation of mesenchymal tissues such as blood, fat,17 bone,26,59
cartilage,57 and muscle60. However, MSCs have also been reported to form tissues such as liver61
and lung,62 which are considered of endodermal origin or nerves,17,58,63-65 which are ectodermal
tissue. Therefore, the mesenchymal cells may have greater pluripotentiality than originally
thought.
1.1.5

Stem Cell Plasticity
The differentiation process was traditionally believed to be a progressive downstream

commitment and irreversible in nature. However, more recently studies have challenged this
concept suggesting that once stem cells have ‘committed’ themselves to a specific cell lineage,
they may still be able to transdifferentiate into another cell lineage. This would support a more
flexible system in which cells may quickly respond to changing regenerative cues in the
microenvironment of healing tissues.66 Song and his coworkers reported that once progenitor
cells have differentiated into adipogenic, osteogenic or chondrogenic cell lines,
transdifferentiation of each committed cell line can occur if the cells are aposed to appropriate
inductive culture conditions of the other two cell lines. Transdifferentiation into each of the other
two cell lines was demonstrated through upregulation of mRNA levels of specific factors
associated with adipogenesis, osteogenesis and chondrogenesis.67 Song and his coworkers67 have
suggested that his phenomenon may be due to potential progenitor cell contamination from
possibly multiple stem cells sources within one cell pool or due to cell-to-cell fusion between
progenitor cells and a tissue-specific cells. Also, the potential ability of cells to reverse to a
precursor cell stage through dedifferentiation and subsequent redifferentiation into a different
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lineage has been speculated but requires further investigation. Research is ongoing to
substantiate the validity of this suggested plasticity of stem cells, defined as “the conversion of
the cell of one tissue lineage into a cell of an entirely distinct lineage, with the concomitant loss
of the tissue-specific markers and function of the original cell type and acquisition of markers
and function of the transdifferentiated cell type”.64,68
1.1.6

Embryonic versus Adult Stem Cells
The potential application of stem cells in human tissue engineering has caused

considerable controversy within the academic, public and political arenas. In the layperson’s
eyes, stem cells are commonly associated with embryonic origin and thus associated with the
destruction of human embryos. Therefore, human embryonic stem cell research, under the
current political atmosphere, is restricted to only a few established cell lines. Embryonic stem
cells (ES) are believed to have a much longer lifespan compared with the adult stem cell, which
is directly related to their telomerase activity. Human ES cells have been expanded for up to 250
population doublings69 (PDs) maintaining their pluripotency and normal karyotype. Therefore,
these cells are considered more versatile compared with the adult mesenchymal stem cell.
However, in addition to the ethical issues associated with ES cells, reports that these cells can
form teratomas in vivo have pushed the emphasis of research more toward postnatally derived
stem cells.
Embryonic stem cells are derived70,71 from the inner cell mass (ICM) of the blastocyst
consisting of an outer cell layer, the trophectoderm, which later develops into the placental
corion and a fluid-filled blastocoele containing a cluster of cells, called the ICM. It is still not
clear, however, whether all cells of the ICM are pluripotent and whether ES cells are derived
from a single or a population of ICM cells within the blastocyst.64 Depending on the species,
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blastocysts are approximately 1 week-old preimplantation embryos.72-74 The embryonic ICM
contains pluripotent stem cells (epiblast), which develop into the species-specific organism
consisting of the three embryonic layers, the endoderm, mesoderm, and ectoderm.68 Embryonic
stem cells are defined as capable of differentiation into all tissue lineages68 and have much
longer cell culture longevity compared with adult stem cells, which display replicative
senescence similar to all other eukaryotic cell lines as stated in the Hayflick limit75, a term that
was coined by Burnette in recognition of Hayflick’s discovery.76,77 Interestingly, adult cells will
conform to this predetermined maximum lifespan of approximately 50 cell doublings after
recovery from a frozen state.78
The replicative lifespan has been shown to be directly related to telomerase activity,
which was first sequenced by Blackburn and her coworkers in ciliated protozoa, Tetrahamena
thermophilia. This discovery allowed length measurements of telomeres, which are the cellular
replicometer and which are suspected to shorten in aging cells until a critical telomere length
eventually determines cellular senescence.79 Greider and Blackburn80 discovered telomerase, an
enzyme that adds telomere repeats to the chromosomes and thereby maintains replicative cell
activity such as seen in embryonic stem cells68 and cancer cells.81 Telomerase is reduced in
hemopoietic stem cells (HSC) and variable or even absent in somatic cells.82,83 Embryonic stem
cells have been reported to survive for 1 to 2 years in culture with cell doubling times of 36 to 48
hours.73,84,85 Cell aging through serial propagation in culture is related to other degenerative
changes, which include abnormal cytoplasmic structures, changes in metabolism, loss of methyl
groups, reiterated DNA sequences, reduction of replicative efficiency and growth rate.86
Apoptosis and tumorigenicity are possibly associated with a certain genetic instability of these
aging cells. The putative relationship to cancer has been proposed as signaling pathways, such as
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those regulated through PTEN, notch, sonic hedgehog and wnt, recently reported for
hemopoietic stem cells (HSCs)87-92, are also related to oncogenesis.93 ES cells can replicate
through extended population doublings beyond those manifested for eukaryotic cells. However,
Deasy and coworkers showed that muscle-derived stem cells (MDSCs) can also be expanded
over more than 300 PDs during 225 days in cell culture.93 These cells showed normal in vitro
phenotypic characteristics (ScaI+/CD34+/desminlow) for up to 200 PDs, at which point CD34
was lost from the surface marker profile concomitant with a loss of muscle regeneration,
myogenic activity and increased growth on soft agar. These results demonstrate that adult stem
cells appear to have the ability to replicate long term but that cell aging is inevitable and may be
related to cancer development.
1.1.7

Mesenchymal Stromal Cell Frequency
Pittenger and his coworkers reported MSC frequency in human bone marrow of between

1 per 104 to 1 per 105 nucleated cells.17 Donor age is a factor influencing human MSC
frequency. Their numbers have been reported to decline in an age-related manner from 1 in
10,000 (newborns) to 1 in 2,000,000 (an 80 year-old person).94 Canine32 and feline95 bone
marrow-derived MSC frequency has been reported to be 1 in 2.5 x 104 and 1 in 3.8 x 105,
respectively. Our data show an equine MSC frequency among the total nucleated BM cells of 1
in 4.2 x 103 (based on CFU-F) in young horses ranging in age from 9 months to 5 years.
However, MSC frequency in mice96 has shown considerable variation for primary cell
frequencies (up to ten fold) between individual subjects. Murine bone marrow-derived MSC
frequency determined from CFU-fibroblasts (F)/- adipocyte (Ad)/-osteoctye (Ob) studies ranged
between 1 in 10.8 X 103 to 1 in 3.45 X 104.97 One to 2 orders of magnitude differences in
numbers of bone marrow-derived equine, human17, canine32, feline95 and murine96 MSC
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frequency may be related to differences in the quantitative methods, age of the donor animals or
some biological features unique to a particular species. Low plating density and large culture
volume may influence cell survival relative to microtiter conditions, influencing the detected
number of MSCs. Age-related correlations in MSC frequency or cell doubling times (2.1
days/cell doubling) could not be detected from non-hematopoietic bone marrow (nhBM)
recovered from femoral heads of patients (27-81 years, n = 16) undergoing hip arthroplasty.98
The authors reported MSC frequencies as high as 1 in 13,000 nucleated cells from these patients.
1.1.8

Adult Stem Cell Sources
Adult mesenchymal stromal cells with multipotent differentiation potential can be found

in many different tissues of the body. It is not clear whether mesenchymal cells are recruited in
response to natural cell turnover and replenishment or injury from niches in close proximity to
these sites or from bone marrow. Multipotent cells have been isolated from tissues such as the
lung99, liver99, kidney99, spleen99, thymus99, placenta100, pancreas101 and even the brain102 and
nerves58 as well as mesenchymal tissues such as cartilage99,103, muscle60 and adipose tissue17. In
the horse, bone marrow and adipose tissue are the most useful and accessible sources for MSCs.
The progenitor cells harvested from these sites in other species have the ability to replicate as
undifferentiated cells and to differentiate into various mesenchymal phenotypes, including bone,
cartilage, fat, muscle, tendon and marrow stroma.
1.1.9

Mesenchymal Stem Cell Niches
Under in vivo conditions mesenchymal stem cells are believed to multiply and

differentiate under much more stringent control than their characteristic expansive growth seen
in cell culture conditions. These multipotent cells are believed to reside in specific niches within
their respective tissues, which are responsible to both restrain their regenerative capacity and to
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prevent tumor formation as well as shield them from molecular signals, which could induce their
cell cycle or differentiation. Hence, these niches provide a balance between the benefit of
replenishing the demand for mature cell lineages and avoiding the detriment of uncontrolled
proliferation of progenitor cells.104
The concept of stem cell niches and their prevailing cellular and molecular mechanisms
have only very recently been targeted by research efforts. The most well-defined niches thus far
are those of the hemopoietic stem cell (HSC), the intestinal stem cell (ISC), the hair follicle stem
cell (HFSC)104 and the neural stem cell niche.105 Cancer development is believed to be associated
with aberrations in the control of stem cell proliferation in their niches and therefore they provide
excellent target for therapeutic intervention in cancer treatment.106,107
Osteoblastic cells provide a niche environment for precursor cells such as the HSC.
Genetically altered mice produce osteoblast–specific PTH/PTHrP receptors (PPR) and high
levels of the Notch ligand Jagged-1, which is a HSC growth factor87, which leads to increaseds in
vivo Notch1 activation in HSCs as well as cultured HSC numbers.108 Parathyroid hormone
(PTH) activation of PPR caused an increase in cultured osteoblast and HSC numbers, which was
abolished by γ-secretase, a Notch inhibitor. Furthermore PTH injection increased HSC number
and survival seen after bone marrow transplantation from the wild-type animals.108 It is believed
that direct contact between HSCs and N-cadherin+CD45- osteoblastic (SNO) cells lining the
endosteal bone surface mediate cell proliferation through N-cadherin and beta-catenin molecules
and through BMP receptor type IA (BMPRIA) controlled signaling of bone morphogenetic
proteins (BMP) in osteoblastic cells.109 Signaling pathways such as those mediated through Wnt,
Notch and Hedgehog are also important in regulating HSC growth and proliferation and
modulation of these transcription factors via the inhibition of glycogen synthase kinase-3 (GSK-
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3) activity have been suggested110, yet are not fully understood.104 Bone marrow contains
multiple niches for HSCs such as the endosteal and a vascular niche and it has been suggested
that due to the proximity of stromal stem cells in bone marrow, similar niches are also present for
the adult mesenchymal stem cell.111
1.1.10 Stem Cell Phenotyping
It is important to be able to recognize and identify stem cells based on specific
phenotypic characteristics in order to define stem cell function and their mechanism of tissue
repair. In vivo models employed for the study of mesenchymal or hemopoietic cell “stemness”
allow the localization of these cells based on immunohistochemical detection of stem cell surface
markers. However, attempts to isolate characteristic cell surface markers of a definitive stem cell
phenotype from varying tissue sources have thus far been unsuccessful.58,68 Phenotyping these
cells currently relies on the use of a combination of cell surface markers rather than specific
surface antigens. There are distinctive differences between the different stem cell types with
regard to the presence or absence of hematopoietic antigens, CD14, CD34, and CD45 on
MSCs.17,112 A number of surface markers such as STRO-1, CD14, CD29, CD 44, CD49a, HOP26 (CD63), CD71, CD73, CD90, CD106, CD120a, CD124, and SB-10 (CD166) antigens have
been described for MSCs.14,17,112-114 Surface markers (CD13, CD29, CD44, CD73 and CD90)
have also been used to isolate adipose tissue-derived stromal cells.14 In this study primary
stromal vascular fraction cells expressed these markers to less than 54%, whereas the surface
marker profile of subcultivated ASCs increased to > 90% of positive cells. These results show
that the primary nucleated cell pool in stromal vascular fractions derived from adipose tissue and
the nucleated cell population harvested from bone marrow stroma are heterogeneous in nature
consisting of varying cell types and stem cells at different stages of differentiation, which may
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variably restrict their multipotential. Approximately two-thirds of all marrow-derived stromal
cells show tri-potential when tested under adipogenic, osteogenic and chondrogenic
conditions.17,98 The remaining portion of the cells were bipotential, capable of adipogenesis and
osteogenesis, suggesting that these two differentiation processes are more closely related in their
upstream gene regulation than the control of chondrogenesis. Species-related differences with
respect to stem cell marker expression and the putative plasticity of stem cells can further
complicate the identification of stem or lineage committed cells.115
1.1.11 Effects of Oxygen Tension on Stem Cell Activation
An important difference between stem cell niches in the body and traditional cell culture
conditions is the difference in oxygen concentrations. The use of cultured cells in tissue
engineered constructs or in cell-based approaches introduces a cell previously cultured at 21%
O2, to hypoxic conditions within the implanted tissue environment. Mesenchymal stromal cells
undergo significant metabolic changes under such conditions. MSCs live in close proximity and
metabolic relationship to hematopoietic stem cells suggesting that these cells live in similar bone
marrow niches.116 This tissue is known to be hypoxic at 1 to 2% O2.117 The proliferative effects
of hypoxic conditions within bone marrow on HSCs are well known.118
Oxygen levels are intricately related to self-renewal and differentiation of mesenchymal
stromal cells. Culturing human MSCs under hypoxic conditions of 2% O2 enhanced proliferation
of in monolayer culture and within 3D scaffolds. Hypoxia at 2% also reduced differentiation
processes such as chondrogenesis and osteogenesis whereas at slightly higher oxygen
concentrations (5%) human adipose-derived stromal cells demonstrated the opposite
phenomenon of reduced proliferation rates and increased adipogenesis compared with cells
cultured under traditional 20% O2 conditions. Grayson and coworkers recently showed that
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hypoxia resulted in approximately 30-fold differences in human MSC expansion rates and
multilayer cell growth after confluence had been reached in monolayer cultures.119 Hypoxia also
had a positive effect on mRNA levels of upstream regulators responsible for cell growth, such as
Oct-4 and HIF-2 as well as extracellular matrix proteins such as collagen I, fibronectin and
connexin-43, which is involved in gap junction formation.119 Hypoxia (1%) apparently did not
affect important regulators of adipogenesis such as PPARγ and ADD1/SREBP1c, or downstream
markers such as lipoprotein lipase and aP2. Yet adipogenesis clearly appeared to be induced and
enhanced compared with cells grown under 2% and 21% normoxic conditions, as measured by
lipid droplet and triglyceride accumulation.120
Hypoxia inducible factors (HIFs) are proteins belonging to the family of bHLH-PAS
proteins and act as transcription factors responsible for cellular changes in response to hypoxia.
HIFs bind to hypoxia regulated elements (HRE) at the promoter region of well over 150 target
genes involved in cell metabolism, survival, motility, basement membrane integrity,
angiogenesis, hematopoiesis and a number of other functions.121 HIF proteins consist of an α
(HIF-1α) and β (HIF-1β) subunit. Regulation of HIF activity is largely dependent on the stability
of its α subunit, which increases under decreasing O2 concentrations.122 The DNA binding and
transcription depends on the stability of the HIF-α protein, which needs to bind the constitutively
expressed HIF-β as well as other coactivators such as CBP/p300 within the nucleus at the HRE
sequence.121
Differentiation mechanisms appear to be down-regulated by HIF121 as well as Notch.123
The intracellular domain of Notch is released from the plasma membrane and transported to the
nucleus after proteolytic cleavage in response to Notch receptor binding with Jagged ligands.
The recruitment of Notch and binding to a DNA complex with other coactivators (MAML, CSL
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and p300) leading to downstream activation of target genes such as Hes-1 and Hey-2, requires
binding of HIF-1.121,124
The precise interaction between HIFs, Notch and Oct4, which is predominantly
responsible for regulating ES cell differentiation and the potential interaction with other proteins
such as BMP and TGFβ is still under investigation. TGF has been shown to induce stability of
the HIF-1a through inhibition of PDH2, which is a proline hydroxyase targeting degradation of
the HIF-a subunits under normoxic conditions.125 It appears that low oxygen levels as seen in
intact tissues such as bone marrow will undermine differentiation processes keeping progenitor
cells potentially stored in microenvironments and protected from oxidative stresses.
1.1.12 The Concept of “Stemness”
The true test of mesenchymal stromal cell “stemness” beyond their ability to differentiate
in vitro into specific lineages is the demonstration of tissue functionality in animal implantation
studies and disease models to progress their application in regenerative tissue repair. The ability
of MSCs to self-renew and expand in culture, to differentiate into different cell lines dependent
on the appropriate stimuli, and to regenerate tissue only encompasses part of the MSC potential.
The early experiments in which MSCs were injected into mice under experimental conditions
resembling osteogenesis imperfecta, demonstrated that the procedure resulted in a small but
significant increase in bone strength.126 As recently reviewed by Prockop127 similar functional
improvements were noted in animal models for human diseases such as Parkinson’s disease,
stroke, myocardial infarction and spinal cord injury. Surprisingly, the clinical effect, which was
attributable to the cell-based approach, did not appear to be correlated to engraftment or
differentiation of stem cells. Only few donor MSCs in experiments where human cells were
implanted into immunodeficient mice after induction of coronary infarction through ligation of
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the anterior descending coronary artery were found based on sensitive assays of tracing human
chromosomes in the animal tissues.128 In clinical cases of osteogenesis imperfect, less than 1% of
donor cells were found within osseous and dermal as well as other tissues.126 These results
showed that tissue formation alone could not account for the improvement of the clinical or
experimental conditions, suggesting that MSCs affected the repair process in yet a different
ways.
1.1.13 Immunotolerance
Immunosuppressive effects of MSCs in response to allogeneic transplantation in both
clinical and experimental models suggest that these cells play an important role in this function.
The precise mechanisms by which MSCs are tolerated are poorly understood. However,
experiments show that MSCs can suppress mixed-lymphocyte reactions in culture suggesting
that MSCs may allow tissue repair following allogeneic bone marrow engraftment by inciting
immunesuppression.129 Experimental T cells-mediated autoimmune encephalomyelitis (EAE) in
a murine multiple sclerosis model have shown that the systemic use of MSCs will result in
drastic improvement of the associated symptoms.130 In a caprine femoropatellar inflammatory
arthritis model the use of stem cells resulted in lowering the inflammatory response.131
The mechanisms by which MSCs are believed to avoid allogeneic recognition are partly
related to cell surface phenotype wherein MSCs are positive for MHC class I, but negative for
MHC class II, CD40, CD80 and CD86 markers. While the MHC Class I molecules alone can
incite a T cell response, other surface molecules are required for a secondary response by the T
cells.132 Therefore, it may be feasible to use MSCs in allogeneic transplantations without
immunosuppression in the recipient. Also, MSCS are believed to inhibit CD8+ and CD4+ cells
such as natural killer cells and thereby evade an innate immune response. Therefore, gene-
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modified MSCs have been proposed as a therapeutic instrument for targeting diseases and
medical conditions in which MSCs can introduce healing factors or altered genetic sequences to
replace the body’s own defective codes “under the radar” of the immune system’s vigilant
guard. MSCs have been used as carriers for interferon-β delivery to tumors in mice.133 Also,
gene therapy with genetic codes for vascular endothelial growth factor has been shown to
improve myocardial function in infracted rats134 135, bone formation through the delivery of
BMPs136-138 and osteopenia via the delivery of merely a normal collagen type I gene into young
humans with skeletal malformations due to osteogenesis imperfecta.126,139
MSCs may be able to provide immune-suppressed microenvironments and therefore
modulate T cell reactions through the synthesis and release of a multitude of soluble
factors140,141, prostaglandins and interleukins such as IL-10142 or through direct cell-to-cell
contact.143
1.1.14 Mesenchymal Stem Cell Trophism
MSCs used as feeder cells in co-culture with hematopoietic cells were found to produce
copious amounts of cytokines and chemokines in culture.144 The patterns of these secreted
factors changed once the cells were injected into new environments such as the brain, which
suggested that MSCs promote repair of damaged cells. Hence adult marrow-derived
Mesenchymal Stem Cells (MSCs) are now known to exert these trophic effects on their
environment by secretion of a variety of cytokines and growth factors, which act in paracrine and
autocrine fashion by suppressing the local immune system, inhibiting fibrosis (scar formation)
and apoptosis, enhancing angiogenesis, and stimulating mitosis and differentiation of other stem
cells intrinsic to the damaged tissues.145 These trophic effects represent a separate function of
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stem cells apart from the direct differentiation into committed cell lines required to regenerate
injured tissue.
Potapova and coworkers have shown that human MSCs (hMSC) cultured in monolayer or
as three-dimensional aggregates in hanging drops (spheroids) secreted vascular endothelial
growth factor (VEGF), basic fibroblast growth factor, angiogenin, procathepsin B, interleukin
(IL)-11, and bone morphogenic protein 2, which affected endothelial cell migration, extracellular
matrix invasion, proliferation, and survival in vitro.146 The concentrations of these paracrine
factors increased 5-20 times in medium conditioned by hMSC spheroid cultures. Differences in
stimulation of in vitro endothelial cell survival and in vivo umbilical vein endothelial cell
proliferation, migration, and basement membrane invasion were noticed between media
conditioned by hMSC spheroids and those conditioned by monolayers of hMSCs.146 Examples of
the indirect MSC effects on its environment through induction of trophic factors are the release
of cytokine such as granulocyte colony-stimulating factor (G-CSF), stem cell factor, macrophage
colony-stimulating factor (M-CSF) and interleukins such as IL-6, which are known supporters of
hematopoiesis.147 The MSCs are attracted to injured tissue sites by chemoattractant factors such
as stromal-cell-derived factor 1 (SDF-1), which mobilizes CD117-positive MSCs, or endothelial
progenitor cells, from the circulatory system to the ischemic and injured tissue such as an
infracted myocardium.148 The release of G-CSF from MSCs or other inflammatory cells will also
have a direct mobilizing effect on recruitment of additional MSCs.149 Hence, MSCs are closely
involved with a multitude of processes, which support different aspects of tissue repair, further
demonstrating the potential importance of these cells in the tissue repair process via systemic or
direct delivery through properties other than cell differentiation and replacement of injured
tissue.
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1.1.15 Stem Cell Homing
One of the important attributes of stem cells, which is still poorly understood, is their
ability to specifically home onto injured tissues. It is known that adhesion molecules, chemokine
receptors and their ligands are important for tissue-specific homing of leukocytes as well as
hemopoietic stem cells. Information is also slowly becoming available regarding the expression
of these receptors and adhesion molecules in mesenchymal stem cells. Studies that show MSC
localization predominantly in ischemic injured tissues, such as experimentally-induced
myocardial infarctions in rats, suggest that MSCs deposited in the left ventricular chamber are
attracted by and directed to specific receptors and ligands in these injured tissues.150
Interestingly, this particular study also showed that the infused MSC localization within the
injured heart soon dissipated (within 4 hours).151 Cells infused intravenously appeared to get
trapped within the lung parenchyma. This effect can be avoided using vasodilators such as
sodium nitroprusside.152
Understanding of MSC homing requires appreciation of MSC expression of chemokines
(CCR1, CCR2, CCR3, CCR4, CCR7, CCR9, CCR10, CX3CR1, CXCR2, CXCR3, CXCR4,
CXCR5 , CXCR6)153-158 and their receptors from the different chemokine families, integrin
molecules such as α1, α2, α3, α4, α5, αv, β1, β3, β4 and other adhesion molecules such as
VCAM-1, ICAM-1, ICAM-3, ALCAM and endoglin/CD105.151,159,160 These molecules may be
of specific importance in certain tissues such as the integrin VLA-4 and adhesion molecule
VCAM-1, which have been found to be crucial in human MSC attachment to the endothelium.
Considerable variability within the literature regarding the chemokine expression has been
attributed to the heterogeneity of MSCs and their potential to home toward different tissues.151
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1.1.16 Mitochondrial Transfer and Stem Cell Fusion
MSC support in tissue repair was found when MSCs were cocultured with modified
endothelial cells (A549 ρ0 cells) containing non-functional mitochondria. The coculture resulted
in colonies of functional A549 cells with MSC mitochondrial DNA but no genomic MSC donor
DNA.161 The process occurred through a direct exchange of mitochondria or mitochondrial DNA
between A549 ρ0 cells and MSCs without cell fusion. However, spontaneous fusion has been
reported between ESCs and co-cultured somatic cells, resulting in a stem cell biomarker
transfer.162,163 In the context of investigating stem cell plasticity, these studies appeared added
confusion because in order to determine plasticity between differentiated cell lines robust
techniques for detection of stem cell fusion are required.164 Reprogramming of somatic cells
using fusion partners such as embryonic stem cells, embryonic germ cells, embryonal carcinoma
cells and undifferentiated cells designed to reset gene expression to embryonic state without
altering the DNA is an emerging tool based on epigenetic mechanisms designed for future cellbased therapies.164
1.2

Multipotential and Differentiation Pathways
After cell culture experiments have established the self-renewal potential of

mesenchymal stromal cells from varying tissue sources, it is necessary to demonstrate their
multipotential characteristics by induction of stem cells into adipogenic, osteogenic and
chondrogenic cell lineages.
Molecular mechanisms of differentiation have still not been completely elucidated. Baksh
and her coauthors have recently proposed that adult stem cells undergo differentiation into
separate compartments, the first of which is governed by transcriptional modification of the
multipotent MSC without phenotypic change, followed by the second compartment, which is
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characterized by phenotypic modification of the precursor cell into a specific cell line.58
Mesenchymal stromal cells reside within their respective niches and remain quiescent and
arrested in the G0/G1 stage of the cell cycle until an environmental signal such as a growth
factor stimulates proliferation and eventually differentiation.58 It is believed that the MSC cell
devision is asymmetric resulting in two daughter cells, one of which is an exact replica of the
original cell and the second is a precursor cell that contains a different genetic transcription
pattern compared with the mother cell. The precursor cell further divides to give rise to bipotent
and tripotent precursor cells, which morphologically still resemble the multipotent stem cell but
may then further differentiate into unipotent cells eventually giving rise to varying cellular
phenotypes such as those osteoblasts, adipocytes, chondrocytes, myocytes or tenocytes. The
regulation of transitions between the multipotent, partially committed precursor cells and the
fully committed cells is not completely understood. However, it is known that there is a temporal
relationship in which cytokine growth factors and extracellular matrix proteins interact with
multipotent and committed precursor cells. In the search for common control genes between
differentiation pathways such as osteogenesis, adipogenesis, and chondrogenesis, experiments
have been conducted to examine expression profiles of 39,000 transcripts that showed at least a
1.5-fold increase in RNA levels after induction. The results showed that 914, 947 and 52 genes
are activated during osteogenesis, adipogenesis and chondrogenesis, respectively, whereby
approximately 25% (235) of the genes upregulated during osteogenesis and adipogenesis are
common to both differentiation processes as opposed to 10 and 3 between adipogenesis and
chondrogenesis or chondrogenesis and osteogenesis, respectively.58 A total of 8 genes (period
homolog1 [PER1], nebulette [NEBL], neuronal adhesion molecule [NRCAM] FK506 binding
protein 5 [FKBP5], interleukin1 type II receptor [IL1R2] zinc finger protein 145 [ZNF145],
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tissue inhibitor of MMP4 [TIMP4] and serum amyloid A2) were common to all three
mesenchymal lineages differentiation processes, suggesting that these genes possibly represented
a form of master control or were genes responsible for regulation of cellular processes common
to all three lineages, such as cell adhesion, organization of the actin cytoskeleton and
inflammatory pathways.58 The relative abundance of common genes during adipogenic and
osteogenic differentiation suggests that these two processes are more similar and may therefore
share common precursor cells, compared with the chondrogenic differentiation process.
1.2.1

Adipogenesis
Adipose tissue was traditionally considered a storage depot for energy up until the 1980s.

Since then, however, molecular biological techniques have completely altered our understanding
of the role of adipose tissue in the body. A variety of gene products were isolated from adipose
tissue such as adipsin, tumor necrosis factor (TNF)-alpha, plasminogen activator inhibitor-1 as
well as adipokines such as leptin165 and adiponectin,166 and it was found that these factors were
regulatory during energy homeostasis under feeding and fasting conditions. Additionally it has
been shown that adipose tissue is related to insulin sensitivity and obesity, as well as in
artherogenesis and inflammation.167 Contrary to suggestions of the older literature that
individuals are born with a set number of adipocytes, it is now believed that based on evidence of
3

H-thymidine incorporation into new adipocytes in rats fed high caloric diets, that adipogenesis

occurs throughout the life time of an individual or animal and that therefore obesity is governed
by adipocyte hypertrophy and hyperplasia.168
Adipogenesis and associated tissue engineering applications are important considerations
in human medicine due to injuries and diseases such as burns, avulsions, lipodystrophy, postsurgical defects after breast tumor removal and congenital defects such as Poland syndrome or

25

Romberg’s disease, all of which often cause tissue defects due to absence or loss of adipose
tissue and therefore significant cosmetic dissatisfaction. Current approaches to correct such
defects with dermal or free adipose tissue grafts, collagen injections and synthetic materials have
major disadvantages such as immune reactions, shrinkage, absorption and fibrous tissue and oil
cyst replacement as in the case of free adipose tissue grafts. The aim is to design soft tissue
scaffolds which are large enough to provide cosmetic relief to the injured tissues and which can
integrate into the recipient’s tissue bed thereby replacing the current use of artificial devices such
breast implants. The engineering is challenging because scaffold size and pore size limit to cell
seeding and adipocyte growth and expansion.
Equine veterinary medicine, however, does not currently have much use for such
cosmetic interventions and therefore it begs the question as to why adipogenesis is an important
factor to consider in our efforts to study the multipotential of equine stem cells. As previously
alluded to it is conventionally considered one of the three pillars of differentiation through which
cells will demonstrate their multipotential capacity. However, it also known that adipogenesis
and osteogenesis are intimately related to each other and with the more recent discoveries of
adipokines and their important endocrine functions within the body, adipose tissue has gained
recognition beyond its functions of energy storage and a physical protection of underlying
tissues. Therefore, it is important to appreciate the intricacies of adipogenic and osteogenic
control as it may provide an understanding for future therapeutic interventions in non-union or
mal-union of bone healing, which is a recognized problem in equine veterinary medicine.
1.2.1.1 Molecular Control of Adipogenesis
Adipogenic induction is typically achieved with induction media containing ligands for
nuclear hormone receptors involved in both adipogenesis and/or osteogenesis, such as
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dexamethasone for the glucocorticoid receptors or indomethacine and thiazolidinediones for the
peroxisome proliferator activated receptor (PPARγ). The following is a description of the
molecular, transcriptional, cellular and hormonal controls known to regulate adipogenesis.
The very early molecular events determining a primitive mesenchymal precursor cell to
differentiate into an adipocytic lineage remain unknown. Characteristic for the first stage of fat
cell differentiation is an initial growth arrest which is then followed by several cell divisions,
known as clonal expansion.169 During this process the transcription factors peroxisome
proliferator-activated receptor-γ (PPARγ) and CCAAT/enhancer binding protein (C/EBPα) are
expressed, which in turn are associated with a second growth arrest followed by complete
differentiation. It is believed that PPARγ and C/EBPα have antimitotic properties. The activation
of PPARγ appears to correlate with the demise of the DNA binding activity of E2F/DP, which is
an important regulator for many genes associated with cell growth and promoting cell
division.170 A number of different preadipocytic cell lines such as the 3T3-L1 and 3T3-F442A
isolated from nonclonal Swiss 3T3 by Green and colleagues171,172 as well as TA1173,174 and
Ob1771175,176 have been used to conduct studies regarding adipogenesis. These cells are
indistinguishable from fibroblasts but are already committed to an adipocytic lineage and
therefore will differentiate readily into mature adipocytes within 4 to 6 days when exposed to
agents such as cAMP, insulin or glucocorticoids. In 3T3-L1 cells, the transition from a growtharrested preadiocyte to a fully differentiated fat cell has been reported in association with a
PPARγ mediated induction of cyclin-dependent kinase inhibitors such as p18 (INK4c) and p21
(Waf1/Cip1). C/EBPα has also been associated with the expression of p21.
Prior to differentiation into mature fat cells the preadipocytic cell enters a second period
of growth arrest following clonal expansion. Attempts to define the beginning and the end of the
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adipogenesis process in culture are difficult, because the process is asynchronous in nature
occurring progressively in cell clusters making mRNA level expressions patterns difficult to
determine. However, it appears that adipogenesis is subject to a cascade of events. An early
biomarkers of the differentiation process is lipoprotein lipase. The appearance of this protein is
closely followed by a number of transcriptional factors, which result in the expression of the
mature adipocyte phenotype and the production of a number of adipogenesis end products. These
include glycerophosphate dehydrogenase, fatty acid synthase, the adipocyte-specific fatty acid
binding protein (aP2), malic enzyme, the glucose transporter GLUT 4, the insulin receptor and
considerable triglyceride accumulation.
1.2.1.2 Transcriptional Control of Adipogenesis
The key players involved in the transcriptional cascade of adipogenesis are members of
the CCAAT/enhancer binding protein (C/EBP) family, especially C/EBPα, C/BEPβ, and
C/EBPδ, the transcription factors peroxisome proliferator-activated receptor-γ (PPARγ). PPARγ
ligands, such as the thiazolidinedione (TZD) class of anti-diabetic drugs, bind with a range of
affinities (Kd = 50 – 700 nM). Other ligands such as 15 deoxy-Δ12,14 prostaglandin J2 (15dPGJ2)
and polyunsaturated fatty acids such as oleate and linoleate177,178 may also bind to PPARγ but
with much lower affinity (Kd = 2 – 50 μM range).
The CCAAT/enhancer binding proteins belong to the family of basic leucine zipper class
of transcription factors and they appear to play a role in both adipogenesis and osteoblast
development.179,180 These proteins have a profound effect on the fat cell maturation of cultured
preadipocytic cell lines under adipogenic induction. It is known that mRNA and protein levels of
CEBPβ and C/EBPδ will rise early during adipogenesis followed by C/EBPα which is induced
later in the differentiation process, before other end-product genes of fat cells.179 The role of
28

C/EBPs in adipogenesis has been studied with the help of knock out mice181, antisense RNA
experiments blocking the expression of factors like C/EBPα and embryonic fibroblast models
lacking C/EBPβ and/or in combination with C/EBPδ.182
The peroxisome proliferator-activated receptor-γ (PPARγ) is part of a heterodimer
formed with retinoid X receptor (RXR).179 PPARγ was discovered through cloning specific
trans-acting factors which bound to the cis-elements (ARE6 and 7 and ARF6) found within the
enhancer located within the 5’flanking region of aP2. PPARγ governs the function of most
adipocyte-specific genes and is required for the fat-selective enhancers within the genes
encoding aP2, lipoprotein lipase (LPL)183 and phosphoenolpyruvate carboxykinase (PEPCK), the
rate-limiting enzyme of gluconeogenesis.184 In most models of diabetes, gene expression of
PEPCK is enhanced in the liver and believed to contribute to the increased hepatic glucose
output.185
As stated earlier, transcriptional control of adipogenesis follows along a cascade of
events whereby hormonal cues may initially activate CEBPβ and C/EBPδ, which then activate
expression of the PPARγ-RXRα complex subsequently causing the activation of C/EBPα. The
factor ADD1/SREBP1 is also induced during adipogenesis and is regulated in response to
variations in food intake.186,187 The exact role of is still not completely understood but its
contribution to adipogenesis in regulating triglyceride and fatty acid metabolism has been
established. It is considered a weaker stimulus for adipogenesis compared with PPARγ or the
C/EBP proteins179, yet it is believed that ADD1/SREBP1-expressing cells in conditioned
medium can activate PPARγ directly or indirectly via promotion of an endogenous PPARγ
ligand.187 Adipocyte determination and differentiation-dependent factor 1 (ADD1) is a member
of the basic helix-loop-helix leucine zipper (bHLH-LZ) family of transcription factors that binds
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to two distinct DNA sequences and has been associated with cholesterol homeostasis, adipocyte
development, and expression of fatty acid synthase (FAS) and lipoprotein lipase (LPL), two key
regulators of fatty acid metabolism.186
1.2.1.3 Cellular and Hormonal Control of Adipogenesis
Hormonal induction of adipogenesis involves activation of preadipocyte IGF-1 receptors
(IGFR) by IGF-1 or insulin leading to activation of two separate signal transduction pathways,
Akt and Ras, which activate adipogenesis via currently unknown effectors. Cyclic AMP (cAMP)
is induced via methylisobutylxanthine (MIX) contributing to adipogenic differentiation by
induction of C/EBPβ either via the cAMP element binding protein or other unknown
mechanisms. Two further adipogenic activation pathways are mediated either through
glucocorticoids which bind to the glucocorticoid receptor (GR) and thereby resulting in C/EBPδ
activation and preadipocyte factor (Pref1) repression. Pref1, a preadipocyte cell surface
glycoprotein, has also been implicated in mediating an antiadipogenic effect of growth hormone
(GH) in rats.188 A variety of growth factors and cytokines act as inhibitors of adipogenesis
affecting mitogen-activated protein kinase (MAPK) which phosphorylates PPARγ and its
heterodimerization partner RXR.
1.2.2

Osteogenesis
Work by Pittenger17, Muraglia 189and their coworkers has shown that only about 30% of

human MSCs have tri-lineage (adipogenesis, osteogenesis, chondrogenesis) differentiation
potential. The heterogeneity of the differentiation potential was further underlined by the fact
that the remaining two thirds of the cells were either bipotential, capable of adipogenesis and
osteogenesis, or unipotent in chondrogenesis.189 These data suggested that there may be a closer
relationship with regard to the upstream regulatory control genes or even common precursors
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between adipocytes and osteoblasts compared with chondrocytes.58 With the help of DNA
microarray technology the profiling of global gene expression has allowed to investigate patterns
gene activation during the three differentiation processes. It has been shown that among 39,000
transcripts 914 responded to osteogenesis, 947 to adipogenesis and 52 during chondrogenesis at
levels of 1.5 or higher compared with controls. A total of 235 genes were shared by osteogenic
and adipogenic differentiation where as chondrogenesis only shared 3 and 10 genes with
osteogenic and adipogenic differentiation processes, respectively. Eight genes were upregulated
during all three differentiation events. These genes included period homolog1 (PER1), nebulette
(NEBL), neuronal adhesion molecule (NRCAM), FK506 binding protein 5 (FKBP5) interleukin
1 type II receptor (IL1R2), zinc finger protein 145 (ZNF145) tissue inhibitor of
metalloproteinase 4 (TIMP4) and serum amyloid A2.58 These genes are known to regulate a
variety of basic cellular housekeeping processes including cell adhesion, protein folding and
inflammation rather than representing master control genes.
The transcription factors regulating adipogenesis have an inverse relationship in the
control of osteogenesis.167,190,191 Certain conditions that enhance adipogenesis, such as
glucocorticoid treatment, ovariectomy, immobilization and aging leading to increasing numbers
of adipocytes and osteopenia.192-195 It has become increasingly more evident during the 1990s
that mesenchymal stromal cells were able to assume both osteoblastic and adipocytic phenotype
suggesting possible transdifferentiation mechanisms, which may naturally be related to the
proximity of marrow adipose tissue and bone.167,196,197 The close but reciprocal balance between
osteoblastogenesis and adipogenesis has stimulated discussions of how this relationship may be
used in the future for therapeutic interventions.
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1.2.2.1 Molecular Control of Osteogenesis
PPARγ is an important transcription factor involved in osteogenic regulation. The ligands
for this nuclear hormone receptor are known to inhibit osteogenesis. The importance of the
PPARγ and its ligands involved in this process is evident from studies in which PPARγ-deficient
mice spontaneously demonstrated osteogenesis but failed in adipogenesis.198 High affinity
ligands such as rosiglitazone were able to increase adipogenesis and concurrently reduce bone
density, whereas osteogenesis seemed to be affected by the low affinity ligand troglitazone.199,200
Similar to other transcription factors such as Lef1 and Twist, PPARγ binds to the runt homology
DNA (RDH) binding domain and thereby inhibits the DNA binding site for the runt-related
transcription factor Runx2/ Cbfa-1 (core binding factor alpha), which is a central regulatory
protein for osteoblastogenesis.201
Runx2 expression appears early during embryogenesis within the prechondrocytic
mesenchyme in two isoforms, the ubiquitous MRIPV Runx2 and the osteoblast-related MASNS
which later become involved in bone formation. Unlike most other transcription factors, Runx2
is also expressed in post-mitotic stages of mesenchymal cell division, which is believed to
augment MSC commitment into and osteogenic phenotype. The differentiation process, requires
an arrest of the cell cycle, similarly as described above during adipogenesis, and Runx2 is known
to affect downstream target genes, the CDK inhibitors (CKIs) p21 and p27, which inhibit
progression into the S-phase.
Thus Runx2 plays a critical role in determining the fate of cell differentiation during the
development of bone. It functions as a molecular switch in determining processes of osteogenesis
and chondrogenesis and is closely intertwined with other regulatory processes such as Wnt/bcatenin signaling pathway which activate Runx2 in MSCs via the Tcf1/Lef1 regulators to induce
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osteoblastogenesis.201 Furthermore, Runx2 expression is controlled by down-regulation through
the Nkx3.2 homeodomain after its induction by BMP2. Both Sox9 (Sry-type high mobility group
box containing gene 9) and the Nkx3.2 are required for chondrogenesis during the endochondral
bone formation process.202-205 The control of prechondrogenic expression of Runx2 by Nkzx3.2,
as well as PTH/PTHrP, is considered a key point in determining chondrogenesis. It is necessary
to undermine premature bone formation and to allow MSCs commitment into the chondrogenic
linage.201 In turn, Runx2-dependent activation of vascular endothelial growth factor (VEGF),
matrix protein collagen type X and the matrix metalloproteinase MMP9 are required for
endochondral ossification subsequent to the hypertrophic chondrocytes stage during which
Nkzx3.2 is down-regulated.206,207 CEBP and Runx2 (Cbfa1) also act synergistically to enhance
osteocalcin (OC) expression.
1.2.3

Chondrogenesis
The enormous economic implications and the loss of horses due to osteoarthritic and

degenerative joint diseases in horses has made chondrogenesis and the cytokines and growth
factors involved in the differentiation and maturation process of cartilage repair a important
focus of equine orthopedic research. As discussed below in the section on cartilage repair in
horses, it is now generally accepted that certain growth factors such as insulin-like growth factor1 (IGF-1) and transforming growth factor-beta1 (TGFβ1) are important substances, which may
benefit cartilage healing as an exogenous source during the early healing phase, or through
genetic modification of chondrocytes or progenitor cells. As discussed earlier, stem cells affect
tissue healing through cytokine release and immunemodulation in addition to tissue regeneration.
Therefore, these cells are considered an essential for the repair of cartilage. However, there is
now increasing evidence that mesenchymal stromal cells from varying equine tissue sources are
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not all created equal. Koerner and coworkers compared bone marrow and peripheral blood
progenitor cells and reported that only stromal cells derived from bone marrow were capable of
chondrogenesis in a pellet culture model.208 Giovannini and coworkers, however, showed that
equine blood-derived fibroblast-like cells do express proteoglycans in pellet cultures and
concluded that these cells are capable of chondrogenesis yet are inferior to bone marrow-derived
cells.209 Koch and his coworkers showed that pellet cultures derived from cord blood progenitor
cells stain for glycosaminoglycans (saffarin O) and showed cartilage morphology with lacunae
containing chondrocytes.210 Collagen type II expression, however, was not examined in this
study. Most recently Kisiday and his coworkers have compared the chondrogenic potential of
bone marrow and adipose tissue-derived mesenchymal stromal cells in agarose and peptide
hydrogel cultures with or with out treatment of TGFβ1.211 The results again demonstrate the
superiority of marrow stromal cells which produced more aggrecan-like proteoglycans under
both hydrogel culture conditions compared with ASCs. Histological anaylaysis of hydrogel
cultures containing TGFβ1 for proteoglycan and collagen type II containing matrix as well as
collagen type II expression evaluated with RT-PCR was only detectable in MSCs but not ASCs.
Other work has shown that human ASCs cultured with TGFb1, ascorbate and
dexamethasone have similar biochemical marker profiles to those of articular chondrocytes.212-216
Awad and coworkers showed that human ASCs appear to demonstrate adequate chondrogenesis
when cultured on agarose, alginate and gelatin scaffolds despite differences in protein and
proteoglycan synthesis between the different scaffold cultures.217 Considering the biological (cell
viability and morphology), biochemical (protein, proteoglycan, glycosaminoglycan and
hydroxyproline synthesis) and mechanical properties (compressive modulus) the gelatin scaffold
appeared to perform best overall followed by alginate and the agarose scaffolds.217 More recently
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Hennig and coworkers compared the chondrogenesis between ASCs and MSCs under the effects
of BMP6 and TGFβ1.218 It was found that ASCs showed reduced messenger level of BMP-2,-4,
and -6 and failed to show significant mRNA levels of TGFβ-receptor-I. Accordingly, ASCs did
not a show significant chondrogenic response when just treated with TGFb1, even at increased
concentrations of 50ng/ml. The combination of TGFβ1 and BMP6, however, improved the
chondrogenic capacity by similar levels of gene expression (aggrecan 1 (AGC), collagen alpha 1
type 2 (Col2A1), and COMP) as those seen for MSCs just under TGFβ stimulus. These results
confirm earlier work by Im and coworkers who demonstrated inferior matrix production in ASC
cultures compared with MSCs cultures and further supports the results of Kisiday’s work, which
also showed nominal responses of ASCs to TGFβ1 compared with MSCs.
Hegewald219 and coworkers have provided evidence that the joint environment itself is an
important chondrogenic stimulus to mesenchymal cells within the joint as the synovium is a rich
source of mesenchymal stromal cells capable of chondrogenesis.220,221 Hegewald’s work has
shown that hyaluronic acid or autologous joint fluid can induce in vitro chondrogenesis in pellet
cultures. Proteoglycan expression was increased due to addition of hyaluronic acid or varying
concentrations of autologous joint fluid, but relatively lower compared with MSC cultures under
chondrogenic induction with TGFβ1. Immunohistochemistry showed that the addition of 5, 10 or
50% synovial fluid concentrations to the chondrogenic protocol had significant effects on
collagen type II expression.219
The effect of synovial fluid is most likely related to growth factor release from soft
tissues such as the synovium, the different types of synoviocytes and its progenitor cells. The
effects of IGF-1222, TGFb1211,222,223, fibro blast growth factor-2 (FGF2)224 on MSCs have been
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studied by several groups and have all shown to enhance the chondrogenic potential of MSCs or
even ASCs.
1.2.4

Current Knowledge about Equine Mesenchymal Stromal Cells
Equine stem cell biology includes mesenchymal cells from different tissues other than

bone marrow and adipose tissue. Table 1 summarizes the main findings on all stem cell types
thus far studied for the horse including adipose- and bone marrow-derived mesenchymal stromal
cells, embryonic stem cells, and peripheral blood- and cord blood-derived progenitor cells. The
research efforts on equine ESCs, however, are more comprehensive and therefore deserve a more
discussion at this point.
1.2.5

Multipotentiality after Cryopreservation of Stem Cells
Cryopreservation of stem cells is an essential tool in tissue engineering and deserves a

brief discussion. The application of cell-based therapies and gene alterations of stem cells to
increase efficiency and efficacy relies on the complete functionality of these progenitor cells to
undergo differentiation pathways, release cytokines and regenerate tissues after cryopreservation.
Cryopreservation causes damage to the cell via extra- and intracellular ice formation,
dehydration and due to the effects solutions in which the cells are suspended. The rapid rate at
which cells are frozen is important in order to promote vitrification of the freezing solution rather
than crystal formation within the cells.225 The process of freezing causes cellular dehydration
through emigration of water from the cell and intracellular crystallization of water associated
with mechanical damage due to crushing extracellular ice formation.226 Solute concentrations in
non-frozen solutions such as high salt solutions are detrimental to the cell because during
freezing these solutes are excluded from the crystal structure of the ice and thereby cause further
damage to the cell. Conditions which cause an increase in viscosity, depress freezing
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temperatures and cause rapid cooling are believed to promote vitrification, a process
characterized by amorphous ice formation rather than crystalization.225 Prior to cryopreservation
cells and other small biological tissues are readily penetrated by cryprotectants such as ethylene
and propylene glycol, glycerol, dimethyl sulfoxide (DMSO) and trehalose. Cells can easily be
frozen in temperatures of liquid nitrogen of -196°C. Combinations of cryprotectants are less
toxic and therefore more effective than a single agent.227
The expansion ability of stem cells after cryopreservation has been documented by Xiang
and coworkers who cultured cryopreserved mesenchymal stromal cells obtained from bone
marrow for 15 passages after resuscitation of the cells.228,229 These authors also found that these
previously frozen MSCs were capable of pluripotent differentiation into mesodermal cell lines
such as chondrocytes and adipocytes as well as ectodermal neurocytes under the appropriate
conditions. The identification of the characteristic committed cell phenotype was supported by
both histochemical analysis of safranin O heterochromia and procollagen type II expression in
the case of chondrocytes, lipid droplet accumulation for adipocytes and nestin and neuron
specific endolase RNA expression for neurocytes.228 Human MSCs undergo osteogenic
differentiation based on evidence of increased alkaline phosphatase expression and nodule
formation.26 This group also examined the growth kinetics of these cells and found that
cryopreserved cells showed no significant differences in their self-renewal ability compared with
fresh cells over the course of 10 passages.26 The post-cropreservation osteogenic potential of
MSCs is further supported by Yoshikawa and coworkers who implanted cryopreserved cells after
thawing into hydroxyapatite (HA) constructs and found through histochemical evaluation of in
vitro culture experiments using plated cells and cells seeded onto HA-blocks as well as after
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subcutaneous implantation experiments into syngenic rats, that these cells elicited extensive bone
formation and elevated mRNA levels for alkaline phosphatase and osteocalcin activity.230
The number of cryopreserved cells appears to have an effect on the post-thaw viability of
adipose-derived mesenchymal stromal cells.231 It was found that the optimal cell number for
cryopreservation purposes was approximately 0.5 x 105 cells/ml freezing medium consistent of
10% DMSO, 10% Ham’s F12 medium and 80% fetal bovine serum. The number of alkaline
phosphatase expressing cells required increased three-fold after freezing ASCs compared with
fresh cells. However, this phenomenon was not correlated to colony forming units undergoing
osteogenesis. More work is yet required in the area of stem cell cryopreservation to optimize post
thaw cell viability, which is important to obtain the required cell numbers for cell-based
therapies and implantation techniques in clinical medicine and surgery.
1.3

Current Status of Stem Cell Biology in Equine Veterinary Medicine
The treatment of orthopedic injuries and diseases has rapidly advanced in the past twenty

years with the advent of improved surgical technology, instruments and techniques, such as
through arthroscopy and new and improved implant materials and designs. However, the horse
will always be disadvantaged in its ability to heal quickly and efficiently from significant injuries
such as fractures and tendon and ligament injuries or diseases and developmental conditions such
as a laminitis and subchondral bone cysts. The reason lies within its significant body weight, the
resulting forces on soft and hard tissues, and the horse’s inability to psychologically cope with
ambulatory failure because of its keen fright and flight response. The result of prolonged periods
of significant lameness or non-weightbearing is all too often the laminitic breakdown within the
contralateral foot capsule. Therefore, there is a real need to invent and develop new treatment
techniques which are designed to improve dynamic stability across fracture sites and to increase
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the speed and efficiency of healing. These will help horses regain ambulatory control and use of
their injured tissues to avoid further complications and decrease the significant wastage
particularly common in the competitive equestrian industry.
Particularly painful and debilitating diseases commonly seen in athletic horses are flexor
tendonitis and suspensory desmitis. These injuries are distinct from those observed in humans as
they most often occur as core lesions within the soft tissue rather than complete ruptures such as
Achilles tendon injuries in human athletes.232 Tendon injuries belong economically to the most
important orthopedic injuries related to the loss of use of horses from all aspects of an enormous
equine industry of 9.2 million horses. The equestrian industry contributes $39 billion dollars to
the yearly US economy of which the racing industry alone is responsible for approximately
26%.1 The annual incidence of superficial digital flexor tendon injury seen just in Thoroughbred
race horses ranges from 7 to 43%.233,234 Tendon and ligament injuries are characterized by a slow
and inadequate healing process, owing to the low metabolic rate of tenocytes, mechanically
inferior scar tissue formation, and the highly strenuous demands on these soft tissue structures
during exercise and, especially, competition. The reinjury rate of SDFT injuries is also high
ranging from 67% in Thoroughbred race horses due to the high-speed demands to between 20 to
40% in horses used for show jumping, dressage, polo and other competitive equestrian
disciplines.
In recent years, stem cell-based therapeutic approaches have been used in equine
veterinary medicine to treat the predominantly effected soft tissue structures such as the
superficial digital flexor tendon (SDFT), deep digital flexor tendon (DDFT), or the suspensory
ligament (SL) and its branches. Traditionally these injuries have been treated with a myriad of
therapeutic interventions ranging from blistering and firing tendons to medical and surgical
1

http://horsecouncil.org/economics.html
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treatments. Medical treatments include intralesional or paralesional injections of antiinflammatory drugs, tendon matrix constituents or lysyl oxidase inhibitors to prevent collagen
type 3 cross-linking. Alternative treatments with laser, ultrasonographic, electromagnetic and
extracorporeal shock wave therapies have also been reported. Surgical approaches such as the
superior check ligament desmotomy are used in the hope of producing a favorable mechanical
environment for tendon healing. However, none of these modalities have stood the test of time
and have often produced questionable results and undesirable consequences. Controlled clinical
studies are difficult to conduct due to the lack of client compliance, and experimental in vivo
studies have not provided much more than a 60 – 70 % prognosis of recovery.
It is generally accepted that intrinsic tendonitis or desmitis, characterized by lesions
within the core of the tendon or ligaments, particularly affecting the SDFT, is due to injury
subsequent to repetitive loading and strain. The precise etiopathogenesis and associated
molecular processes have not yet clearly been defined but are most likely explained by a
combination of the current multiple theories related to mechanical, molecular, vascular and
perhaps hyperthermic processes.235 Subclinical and often non-inflammatory events have been
shown to result in either tenocyte overstimulation or understimulation and subsequent gene
expression of catabolic factors causing further degeneration.236 Conversely, in clinical tendonitis
overt inflammation within the lesion secondary to overloading and fibril disruption occur. The
reason that the aforementioned treatment options do not or only partially address the actual
problem of the disrupted tissue, is that most of them do very little to regenerate the actual
structure of the tissue and to prevent the formation of non-elastic scar tissue incompatible with
its natural function of shock absorption.
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The notion that transferring bone marrow into injured tendons may be beneficial to the
healing process within injured tendons was due to the introduction of growth factors and the
potential of resident mesenchymal stromal cells. The original report described an unusually high
success rate of 86% within a population of 100 horses.237 Whereas scientifically debatable, this
report provided important stimulus to further investigate the merit and potential of equine stem
cells and their combination with growth factors and bioabsorbable scaffolding materials, the
three pillars of tissue engineering.
Current cell-based approaches to treating tendon and ligament injuries currently used in
equine veterinary medicine employ the use of supraphysiological numbers of mesenchymal
stromal cells either just isolated from adipose tissue (ASC) or isolated and expanded from bone
marrow (MSC). It is important to recognize the difference between these two approaches, as the
cells isolated from adipose tissue are a nucleated cell pool referred to as the stromal vascular
fraction, that contains a relatively high number of mesenchymal cells (~200,000 ASCs/gram of
fat), but which have not been expanded. MSCs occur in much lower numbers within bone
marrow and therefore have to be expanded in culture before implantation. Cell culture of MSCs
for 10 to 14 days, however, will result in much greater cell numbers than the primary ASC
isolates from the stromal vascular fraction. Hence there are vast differences and variations in the
applied cell numbers between these two treatment options, which may affect tissue healing. It is
currently assumed that these high numbers of MSCs and ASCs will regenerate normal tissue
more effectively compared with the body’s natural ability. Initial reports from clinical data in the
United Kingdom have shown that the use of bone marrow-derived cells appeared to reduce the
re-injury rate in both racehorses and sport horses by approximately 20 to 30%, whereby it
seemed to be important that this therapeutic modality was used early in the course of injury.238,239
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1.4

Gene Delivery in Mesenchymal Stromal Cells
Gene therapy involves the insertion of genetic sequences via vectors such as viruses into

somatic cells, which will change the recipients’ genome but, unlike germline gene therapy, will
not cause inheritance of the genetic alteration to the next generation. Mesenchymal stromal cells
are a potential way to introduce genes for the augmentation of cell differentiation and the
neoformation of tissues. Biologically suitable cell scaffolding and a combination of stem cells
and gene-enhanced cell differentiation are currently considered the most effective manner of
tissue engineering. Genetically modified cells have been investigated in a variety of tissues such
as bone240,241, cartilage242,243, tendons244, brain245 and other nervous tissues246 and the heart247 and
in diseases such as diabetes248 and cancer control249 through the use of hemopoietic stem cells. In
equine veterinary medicine, the predominant application of recombinant proteins and gene
therapy has focused on musculoskeletal diseases such as cartilage resurfacing, fracture healing,
tendon/ligament repair and wound management. Growth factors of potential clinical relevance
are those of the bone morphogenic protein family (BMPs), the transforming growth factor-β
family (TGFβ), insulin like growth factors (IGFs), platelet derived growth factor (PDGF),
fibroblast growth factors (FGFs), epidermal growth factors (EGFs) and activins and inhibins.250
Stewart and co-workers showed that FGF-2 treatment of monolayer marrow-derived MSCs
resulted in increased mRNA level of collagen type II and aggrecan as well as total
glycoaminoglaycan and DNA content from pellet cultures under chondrogenic conditions.224 In
vitro experiments with equine chondrocytes demonstrate that IGF-I appears to have both a
protective function within the joint as well as a role in supporting extracellular matrix growth.
The combination of IGF-I and corticosteroids have demonstrated a protective effect on
proteoglycan degeneration in response to an interleukin (IL)-1 induced inflammatory
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response.251,252 The anabolic effect of IGF-1 appears to be dose-dependent are related to the
matrix synthesis by chondrocytes grown in fibrin discs. Proteoglycan content is augmented by
pretreatment of bone marrow derived MSCs with TGF-β.222,253,254 Equine in vivo models have
shown that treatment of full-thickness cartilage lesions in the femoropatellar joint with human
recombinant IGF-I enhanced fibrin clots resulted in improved collagen type II deposition within
6 months after treatment.255,256 Using scaffolds composed of fibrin and chondrocytes treated
with IGF-I resulted in superior collagen type II deposition compared with controls not receiving
IGF-1.133 The exact molecular mechanisms of this anabolic effect remain to be established.
Messenger RNA levels related to collagen type II and aggrecan expression in cartilage repair do
not appear to correlate with those of IGF-1.257
In the equine athlete, cartilage damage is a sequel to the inflammatory events that occur
in osteoarthritic joints. In osteoarthritis, stem cells are depleted locally, and their proliferation
and differentiation capacity appears to be reduced.258 This suggest the potential value of stem
cell delivery into osteoarthritic joints in the hope of reducing the progressive destruction of the
joint and possibly facilitating repair. Gene enhancement of MSCs in the joint with cartilage
protective growth factors such as IGF-1 and possibly factors which will reduce the inflammatory
process within osteoarthitic joints may well further our investigations toward a successful
treatment for osteoarthritis in the horse and other species. It has been shown in the rabbit model
that the severe inflammatory and proteoglycan destructive effects of intra-articular injections of
human recombinant interleukin-1 beta (hrIL-1 beta) was inhibited by the IL-1 receptor antagonist
(IL-1ra) also referred to as IRAP.259 The use of an adenoviral vector for gene delivery was first
successful in the laboratory animal model.260 Equine synoviocytes cotransduced with IGF-1
and/or IL-1ra coding sequences were able to partially or fully reverse the detrimental effects of
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IL-1 exposure to cartilage explants via AdIGF-I-transduced cultures or AdIGF-I/AdIL-1Ratransduced synovial cocultures, respectively.261 The combination of IGF-1 and IL-1ra has
recently been reported in an elegant study using the same vector model in the horse to treat
microfractured chondral defects. Iatrogenic defects had filled in after 16 weeks of a controlled
rehabilitation regime with levels of proteoglycan and collagen type II significantly above those
of the sham treated controls. Therefore, IL-1ra appears to play a role as a component in the
treatment of arthritis. Gene therapy via cell transduction with this mediator appears to be a
suitable method of delivery. Recombinant IL-1ra proteins are known to have a short half-life of
4 to 6 hours after intravenous administration in humans, requiring molar IL-1ra/Il-1 ratios of 10
to 100 to demonstrate efficacy.262 The use of viral particles as reported in the previously
described study is not suitable for clinical application in animals or humans. The combined
application of gene encoded IGF-I and IL-1ra may further benefit from transduction into
mesenchymal stromal cells. Beyond their obvious function as cell and tissue replacement, other
known advantages such as their cytokine release and anti-inflammatory effects263 are important.
A recent study in sheep using joint destabilization via medial meniscectomy as a model of
osteoarthritis showed that MSC-based therapy had a significant effect on articular cartilage
structure maintenance and the reduction of subchondral sclerosis.131
Most of the research efforts in regenerative tissue repair for musculoskeletal disease in
horses thus far have concentrated on cartilage repair and resurfacing due to osteoarthritis and
trauma induced arthritis, leading to the substantial yearly losses that occur in the competitive
equestrian industries. In contrast to this body of literature, research into stem cell, scaffolding
and growth factor or gene-mediated approaches to fracture and subchondral bone cyst repair,
arthrodesis, and conditions such as malunion or non-union, which are less well described in
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horses compared with humans, dogs and other species has been limited. Fracture repair in the
horse is fraught with many possible complications related to the body weight of these animals
and the susceptibility of laminar tissues in contralateral feet to increased forces during fracture
healing. Bone regeneration has so far been limited to cancellous bone grafts used during the
surgical fracture repair or arthrodesis procedures. MSC implantation into mechanically suitable
scaffolding materials has been investigated in other species for some time. However, due to the
tremendous body weight of the horse, the majority of the literature on fracture repair has focused
mostly on internal or external fixation techniques to allow immediate post-operative recovery
and ambulation on the affected limb. Most scaffolding materials required to fill large fracture
defects are not yet sufficiently strong or have not been tested under the conditions a horse would
impose. However, recent studies in sheep using autologous MSCs seeded onto porous
hydroxyapatite ceramic have been encouraging but will require validation of mechanical
suitability before this material is used in the equine model.264
A recent study using equine MSCs has shown that adenoviral vector transduction of
BMP-2 and BMP-6 resulted in significant upregulation of these two osteogenic factors under
appropriate osteogenic induction.241 The use of a gene-mediated approach showed accelerated
differentiation and ossification of monolayer cultured cells as well as transduced MSCs seeded in
three-dimensional alginate culture systems for both cytokines. BMP-2 transduced cells showed a
very sharp increase (2514-fold) in BMP2 expression during the first 48 hours and subsequently
leveled off after 12 days (20-fold), whereas RNA levels of BMP-6 rose sharply by 2 days (6236fold) after induction but only reduced 10-fold over the course of three weeks, suggesting that
there is a time-dependent role for both of these genes in osteogenesis. Equine-specific microarray
analysis showed that a number of other genes, such as those related to inflammation (IL8,
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CXCL2), osteogenesis (cartilage oligomeric matrix protein [COMP], procollagen α 1, BMP6
precursor, SMAD6, procollagen α-1 type III precursor (COL3A1), parathyroid hormone-related
peptide) and cell differentiation (inhibin β A subunit, keratinocyte growth factor [fgf-7], fibulin1 [FBLN1], and retinoid acid receptor responder [RARRES1]) were upregulated in response to
BMP induction. Genes commonly related to tissue repair, which did not appear to be affected by
BMP-2 or -6 were aggrecan core protein, biglycan, decorin, dermantan sulfate proteoglycan,
fibronectin, insulin-like growth factor II, SOX-9, collagen type II.241
A number of other growth factors may soon be used for genetic enhancement of
mesenchymal stromal cells in the attempt to optimize regenerative tissue repair. Some of the
growth factors which have gained increasing attention for their application for equine
musculoskeletal diseases are the platelet derived growth factor (PDGF) and TGF-β. These
growth factors can be derived from autologous platelet concentrates deposited in injured tissues.
These are presumed to benefit the healing process through degranulation and release of PDFG
and vascular endothelial growth factor. These factors appear to augment neovascularization,
through stimulation of endothelial cells and TGF-β, which is known to stimulate mitosis and
differentiation in osteoblastic progenitor cells and subsequently osteoid production.250 Increased
concentrations of PDGF and TGF-β have recently been reported in a study, which showed that
PRP has anabolic effects on explants of the equine superficial digital flexor tendon (SDFT). This
was determined by quantitative RT-PCR of collagen type I (COL1A1), and III (COL3A1) and
COMP mRNA levels, and it was also found that PRP does not activate catabolic factors such as
MMP-3 and MMP-13.265 Interestingly, acellular bone marrow appears to have even greater
effects on COMP and total protein synthesis of equine suspensory fibroblast cultures compared
with PRP and equine serum.266 Bone marrow supernatant has mostly anabolic effects but factors
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such as age may change the profile of the protein composition in acellular bone marrow as a thus
far unidentified protein in bone marrow supernatant has been reported to have inhibitory effects
on osteoblast proliferation in aging rats.267 The promotive effect of platelet-rich plasma derived
growth factors on differentiation and tissue regeneration in wound healing involves thrombin
activation, platelet degranulation and growth factor release leading to improved epithelial
differentiation and improved collagen bundle organization.268 Platelet-rich plasma enhances bone
healing in defects around canine dental implants.269
1.4.1

Cartilage Repair
Cartilage degeneration associated with osteoarthritis is one of the major orthopedic

concerns in both human and veterinary medicine. Hence, cartilage repair has been investigated
for many years with promising advances in scaffold material development as well as growth
factor and cell integration. A cartilage repair protocol as reviewed recently by Caplan5 consists
of expanding MSCs collected from bone marrow in monolayer culture before seeding upon
fibronectin-coated hydroxyapatite (HA) sponges. The high-molecular weight HA has been found
to be chondroinductive270,271 and anti-angiogenic. Studies using MSCs in implanted vascularexcluded porous CaP ceramic vehicles have shown that an avascular microenviroment
encourages MSCs to form cartilage. Furthermore the oligomers of the degraded HA scaffold
trigger the neovascularization of hypertrophic cartilage followed by replacement with
vascularized bone and the integration of the neocartilage with the host cartilage.272-274
The use of growth factors such as insulin like growth factor-1 (IGF-I) integrated into a
fibrin base to recruit stem cells from within the cartilage and the deeper layers of an equine
femoral trochlear ridge cartilage defect model has been examined showing that.275 Also,
chondrocyte and MSC integration into a fibrin base has been investigated and the results have
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shown that the fibrin glue itself improved collagen type II concentration (expressed as a
percentage of collagen type I) in the repair tissue from 27% to 43% when compared with defects
that were not filled with fibrin. However, adding IGF-I to the fibrin clot further improved
collagen type II expression to 47%, which was found to be significantly different from just using
the fibrin scaffold without the growth factor. However, adding autologous chondrocytes into to
the fibrin base yielded the best results showing a collagen type II expression of 62%.276
Adenovirus transduction of IGF-1 into chondrocytes has shown to improve healing during the
first 1 to 2 months after injury whereas less benefits were seen after long term-follow-up of the
injury.277 Similar results of an early response in cartilage were also seen when MSCs implanted
into experimental cartilage defects in equine femoropatellar joints.278 These results suggest that
IGF-1 and genetic modification of chondrocytes with IGF-1 as well as MSC implantation have
positive effects on cartilage healing. Further work using other combinations of other scaffolds
such PRP (platelet rich plasma) and stem cells programmed by growth factors and gene
modulations to differentiate into chondrocytes is on the way and has recently been introduced at
the annual ACVS Symposium.
1.4.2

Tendon/Ligament Repair
Equine tendon and ligament injuries are the second most important orthopedic condition

in equine athletes and hence revenue in the competitive equestrian industry every year. The use
of stem cells for tendon repair in horses, however, has been limited to cell replacement therapy
since to date stem cells or bone marrow aspirates have merely been injected without an
additional matrix. Growth factors such as IGF-I, have been used along with stem cells to enhance
collagen type I expression. The use of this growth factor in collagenase-induced lesions has
shown that tendons treated with IGF-I expressed increase Cell proliferation and collagen content
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and there was overall less soft tissue swelling in the treated tendons as compared with saline
treated tendon controls.279 A separate study examining the temporal expression of IGF-I and
transforming growth factor-β1 (TGF-β1), and extracellular matrix proteins collagen type I and
III found that TGF-beta1 expression occurred within 1 week of the would healing process and
therefore much earlier than IGF-I, which peaked 4 weeks after the injury and remained elevated
until week 8.279 Messenger RNA levels of both collagen types remained high for 8 weeks after
reaching their peak within the first 7 days. The conclusion of these studies was that IGF-I is an
important factor in the tendon healing process and that early exogenous IGF-1 administration
may benefit tendon healing by elevating low endogenous levels of the growth factor during the
first four weeks after the injury.
So far no adequate scaffolds have been added into core lesions of tendons along with
stem cells. The only exception is a product with the somewhat misleading name of ACell, Inc.
(www.acell.com), which is an injectable product and does not contain any stem cells. It is a
lyophilized acellular powder, which is derived from extracellular urinary bladder matrix (UMB)
of specific pathogen free (SPF) pigs. ACell has had mixed anecdotal success and after a period
of legal disputes about proprietary rights their products are once again commercially available on
the market again. The only peer-reviewed paper reports that 84.4% of 77 horses with
proximal/body suspensory ligament lesions, 86.7% of 15 horses with suspensory branch lesions
and 92.9% of 14 animals with superficial digital flexor tendon were found to be sound and
returned to work within 12 months or more after treatment.280 Ultrasonographic examination of
the lesions revealed considerable fluid infiltration at 5 and 30 days post injection but had
improved fiber pattern and minimal edema formation by Day 60.
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The use of stem cells for equine tendon and ligament strain injuries was established
during the mid 1990s in the form of bone marrow transfers from the sternum directly into the
tendon lesion. A retrospective study by Herthel237 reported an 86% success rate of horses
returning to work after 6 months. This report suffered from a lack of classification of tendon
lesions, breed heterogeneity and use of the treated equine population as well as a lack of
appropriate follow-up data. The results, however, appeared to provide an impetus in the equine
research community and commercial market. Stem cells are now commercially available for
horses from two different companies. Some companies (VetStem, Inc., Poway, CA, USA;
Evostem Finland Ltd, Kangasala, Finland) isolate autologous stem cells from adipose tissues and
VetStem Inc. has more recently also advertised their services for canine tendon injuries
commonly observed in the dog racing industry. Other companies (VetCell BioScience Limited,
London, United Kingdom) provide autologous stem cell isolates from bone marrow. Since 2002,
the American and British stem cell companies report that between 400 to 600 horses have been
treated and claim approximately 70% prognosis for racehorses to return to racing.281 However,
no controlled studies have so far been undertaken to show the efficacy of these cells to improve
tendon healing. A common measure of a successful tendon repair is if a horse is able to race
three or more times without reinjury and such data are still lacking.
Surgical implants based on collagen-suture scaffolds seeded with mesenchymal cells
have not yet been employed for tendon lacerations exhibiting partial or complete transsection in
horses. However, in rodent models these scaffolds have been successfully used. The constructs
are designed by aligning a suture material under tension within a collagen scaffold and then
seeding the collagen with mesenchymal cells. The transplanted cells will orientate themselves
along the suture material and begin to contract the collagen. Such constructs were used in a
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rabbit Achilles tendon repair model by Young and coworkers282 which resulted in significant
improvement in morphological, structural, material and mechanical properties compared with
simply reapposing the transected tendon with suture material. The inserted constructs improved
cellular alignment and elongation as well as improved fiber bundle thickness and crimp
parameters of the repaired tendon segment.
Synthesis of the first in vitro engineered tendon based on rat Achilles tendon cells which
were first grown to confluence in monolayer culture and later allowed to self-assembly within a
cylinder between two anchor points.283 The resultant scaffold free tissue was composed of
aligned small diameter collagen fibrils and a large number of cells as well as an excess of noncollagenous extracellular matrix and showed structural, morphological and also mechanical
characteristics similar to that of chick embryo tendons.
The search for a mechanically optimal scaffold or engineered tendon implants is ongoing.
Further research is still required to elucidate the tenocytic potential of MSCs and ASCs, the role
of mechanical forces on mesenchymal stem cell differentiation, and the impact of growth factors
and other mediators as well as the cell to matrix interaction to optimize the results of scaffold
development is required.
1.4.3

Bone Repair
Bone marrow transplants provide an osteoinductive and osteoconductive environment for

resident stem cells and have been used in horses to augment repair of bone fractures and joint
arthrodesis procedures.284 While the use of MSCs in bone repair has been extensively
investigated in other species, applications of MSCs for the repair of larger equine fractures have
been hampered by the lack of suitable scaffolding materials. Such materials require a number of
other parameters, the most important of which is that the material is mechanically sensitive to the
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site providing sufficient compressive strength to withstand the rigorous biomechanical demands
of an adult horse. Furthermore, the material has to be porous in nature to allow or encourage cell
attachment and access to bioreactive materials aimed to encourage cellular proliferation and
differentiation. Since most scaffolding materials will have different mechanical properties than
the host tissue, they will either need to be incorporated into the tissue or facilitate bioabsorption.
Such scaffolding materials does not yet exist which will continue to limit effective bone
repair in equine orthopedic surgery. Stem cells and appropriately sized scaffolding materials
would be most beneficial in the repair of large bone defects in fractured equine long bones.
Fracture repair in horses is subject to tremendous mechanical challenges and possible
complications, unlike those that occur in any other species in which osteosynthesis and fracture
repair is commonly performed. The horse’s post-operative survival is largely dependent on its
ability to bear weight on the repaired leg during and immediately after recovery from surgical
correction of a fracture. Therefore, fractures with large bone defects are very instable and despite
internal fixation and coaptive cast stabilization will bear a guarded to poor prognosis.
Bone marrow biopsies harvested intra-operatively from the tuber coxae and less
frequently from the sternum or the proximal medial tibia have been used to augment
osteogenesis, osteoinduction, osteoconduction and osteopromotion for orthopedic procedures
such as fracture repair and arthrodesis techniques. Bone marrow biopsy tissue lacks mechanical
stability and has a relatively low number of progenitor cells per unit weight of tissue, which
limits the use and versatility of this technique. Their use in cystic lesions such as the common
medial femoral subchondral bone cyst in young horses has been met with limited success due to
bone marrow necrosis after implantation into the lesion. Therefore, the rate-limiting step in the

52

tissue engineering for equine fracture repair will be the design of new implant materials with the
appropriate mechanical properties.
1.5

Other Potential Applications of Stem Cells in Equine Veterinary Medicine
Other potential applications for stem cells in equine veterinary medicine including

traumatic and degenerative skeletal condition such as arthrodesis, mal- and non-union during
fracture healing, degenerative joint disease (DJD), dermal injuries, wound management and
vascular diseases such as equine laminitis and ischemia reperfusion injuries after intestinal
insults. While the treatment of intestinal distension-related ischemia reperfusion injuries with
stem cells is still only conceptual, another very significant vascular disease of the horse,
laminitis, has recently received increasing attention.
1.5.1

Equine Laminitis and the Equine Metabolic Syndrome
Acute laminitis is a debilitating, painful, and potentially career-ending and life-

threatening disease of the soft tissues (laminae) of the equine digit. At the pathological level,
laminitis reflects an induced vascular dysfunction afflicting the vasculature of the hoof, which
leads to laminar edema formation, tissue ischemia, activation of additional systemic or local
inflammatory mediators, and enzymatic abnormalities. The ultimate result of these processes is
laminar tissue injury/necrosis, lameness and eventually mechanical failure with rotation or
sinking of the distal phalanx within the hoof capsule. In other words, laminitis destroys the
tissues responsible for supporting the horse by suspension of the distal phalanx within the hoof
capsule.
Laminitis causes high morbidity and mortality for the horse and leads to economic and
emotional costs for the owners. Approximately 15% of horses in the US are afflicted with
laminitis in their life, and 75% of these develop lameness and debilitation necessitating
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euthanasia. Monetary losses associated with equine laminitis are estimated at $13 million per
year associated with diagnosis, treatment and animal loss due to complications. This, combined
with an incomplete understanding of the disease, helps explain why 3,500 equine veterinarians
responding to the American Association of Equine Practitioners (AAEP)-sponsored survey
considered it the most important equine disease and the number one area for future research
(http://www.aaep.org/).
The pathogenesis of laminitis is not fully understood; however, there are a number of
pathological and experimental observations that link this equine disease to human conditions
such as diabetes and Raynaud’s syndrome.285-287 Inactive horses often develop visceral obesity
and subsequently exhibit a “metabolic syndrome” characterized by insulin resistance, glucose
intolerance, hyperlipidemia, and hypertension, a spectrum resembling human type 2 diabetes
mellitus. The onset of acute laminitis routinely precedes the diagnosis of the equine metabolic
syndrome since the metabolic syndrome often goes unnoticed.287 Horses afflicted with laminitis
frequently display a peripheral Cushing-like disorder characterized by elevated levels of serum
glucocorticoid and increased steroid converting enzyme (11β-hydroxysteroid dehydrogenase-1)
activity within the laminar tissues.288-290 In man, clinical investigators have postulated that
localized conversion of glucocorticoids by 11β-hydroxysteroid dehydrogenase-1 in adipose
tissue promotes the onset of metabolic syndrome and type 2 diabetes mellitus.291,292
Overexpression of this enzyme in adipose tissue of transgenic mice produces all of the
physiologic changes expected in metabolic syndrome.291 In vitro studies have determined that
the pathological tissue changes occurring in laminitis result from glucose deprivation and
associated matrix metalloproteinase activation.293 Likewise, in vitro analyses have demonstrated
that equine endothelial cell function is inhibited by homocysteine, a risk factor in man for
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atherosclerosis and small vessel disease.294,295 In summary, equine laminitis represents a small
vessel dysfunction directly associated with a human-like “metabolic syndrome”.
Some of the benefits of adult stem cell application is apparent from studies which have
shown that MSCs from humans296 and rodents297 may readily differentiate into endothelial cells
and are capable of expressing potent angiogenic growth factors298. Arterial infusion of adult bone
marrow-derived stem cell populations has been shown to protect humans299 and rodents300-302
from the necrotic consequences of prolonged vascular ischemia/reperfusion of the hind limb.
These findings support the potential value of adult bone marrow stem cells for the treatment of
horses suffering from acute ischemic injury associated with laminitis.
A number of animal species are used as surrogate models for small vessel disease in man,
including the mouse, rat, dog, and pig. Each of these animals offers certain advantages. Rodents
provide inbred, genetically defined animals available in large numbers at relatively low cost.
The dog and pig, with their larger body mass, provide a vasculature more closely approximating
that of humans. However, large animals such as the horse are rarely used as a preclinical model
due to its cost and the lack of suitable research facilities accommodating its use in most major
medical centers. Nevertheless, horses suffer from diseases relevant to the human condition and
thereby offer a unique opportunity as an experimental model. With its greater size and weightbearing loads, the demands placed on small vessels in the equine model are expected to meet or
exceed those required in man. Thus, this offers the unique possibility to test the safety and
efficacy of an adult stem cell therapeutic in a clinical veterinary setting. The outcome of in vivo
experimental trials will have direct commercial application in veterinary medicine and will
provide a large animal pre-clinical test for future human applications.
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1.6

Conclusions
Equine stem cell biology is just now beginning to blossom and benefits from all the work

that has already been performed in other species. The horse is a unique model as it is the most
athletic domestic animal of all that are likely to receive the benefit of technical advances in
regenerative tissue repair. Most of the diseases currently under investigation in the horse are of
an orthopedic nature, for which cell-based therapy may prove to be useful in augmenting
osteosynthesis for equine fractures, arthrodesis procedures and subchondral bone cysts, tendon
and ligament repair and cartilage resurfacing. However, the horse’s bodyweight and its
unparalleled impressive athletic ability pose the most challenging constraints for tissue
engineering and it is postulated that advances in this species will inevitably translate to
successful therapeutic results in other species such the human and the dog. Therefore, it is
important to strike the delicate balance between the four different constituents of successfully
engineering or supporting the repair of new tissues in the injured equine athlete. Current efforts
are directed toward establishing the basic understanding of the frequency and growth
characteristics of stem cells from varying tissues in culture in order to amplify their numbers
required for tissue engineering. Furthermore it is important to demonstrate the in vitro
multipotential differentiation capacity of equine stem cells before these cells are then further
tested for functionality in the tissues of interest.
The natural environment of stem cells provides a mixture of cell-to-cell and cell-tomatrix cues and these progenitor cells require anabolic factors, an appropriate inductive and
conductive matrix as well as mechanical stimulation to facilitate tissue alignment and maturation
during the healing phase. However, unlike bone, some other specific tissue such as tendons and
ligaments are not capable of providing a sufficient balance of these required factors resulting in
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production of inferior scar tissue predisposing to reinjury in 58% of injured racehorses. Isolation
of progenitor cell populations from adult horses has so far been unsuccessful.303 Mesenchymal
stromal cells isolated from fetal tissues and young horses are believed to reside in the endotenon
adjacent to the vasculature and in-between collagen fascicles, have demonstrated inferior
multipotential compared with that recognized in bone marrow-derived MSCs. Therefore, it is
likely that tendons and ligaments may obtain their requirement for stem cells after injury from a
peripheral blood-derived or adjacent marrow-derived pool of progenitor cells. Current cell-based
techniques have been aimed at using supraphysiogical numbers of MSCs or ASCs. Prospective
studies using MSCs report lower tendon reinjury rates238,239 and ASCs also appear to benefit the
tissue organization after collagenase induced injury.304
1.7
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CHAPTER 2.
CELL GROWTH CHARACTERISTICS AND DIFFERENTIATION FREQUENCY OF
ADHERENT EQUINE BONE MARROW–DERIVED MESENCHYMAL STROMAL
CELLS: ADIPOGENIC AND OSTEOGENIC CAPACITY

____________________
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2.1

Introduction
The postnatal bone marrow contains marrow stromal cells, also known as mesenchymal

stromal1 or stem cells (MSCs).2,3 These cells have the ability to differentiate along multiple
lineage pathways in vitro as summarized in recent reviews on stem cell characterization and
clinical application in human2-7 and veterinary medicine8. Since MSC-based therapeutic
approaches have been investigated for some time in human medicine and surgery, veterinarians
are now considering equine bone marrow-derived MSCs as potential therapeutic agents for
musculoskeletal problems such as tendonitis, desmitis9, as well as bone and joint10-related
conditions in the equine athlete. Recent in vivo studies using a rabbit model have shown that
MSCs can contribute to improved biomechanical characteristics following tendon repair.11,12
Multiple studies document the need for sufficient numbers of MSCs in order to optimize
musculoskeletal tissue repair.3,5,8,13,14 It has been calculated that 70 million progenitor cells are
required to produce a cubic centimeter of bone.15 Cell-based approaches to tendon and ligament
injury repair have employed supra-physiologic numbers of MSCs.9,16 Awad and coworkers,
using a rabbit model, found that greater MSC seeding densities affected cellular morphology and
contraction kinetics in collagen scaffolds.17 Therefore, in order to generate the requisite number
of cells required for tendon and ligament repair, it is necessary to characterize the growth
characteristics of equine MSCs.
The majority of the published work documenting MSC differentiation potential, however,
has been performed in species18 other than the horse, with the exception of the ability of equine
MSCs to undergo chondrogenesis.19. Likewise, cell quantification and expansion data of bone
marrow-derived MSCs have been reported for humans20,21, dogs22, sheep23, rats24, cats25 and
Rhesus Macaques26 but not in the horse.
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Therefore, the objectives of this study were to document and quantify the growth and
differentiation characteristics of equine bone marrow derived MSCs using limit dilution assays
for adipocytes, alkaline phosphatase positive cells, fibroblasts, and osteoblasts. This data will
assist future efforts to standardize the isolation, expansion, and transplantation of equine MSCs
in clinical practice.
2.2
2.2.1

Materials and Methods
Materials
All chemical reagents were obtained from Sigma Chemical Co. (St. Louis, MO, USA) or

Fisher Scientific International Inc. (Hampton, NH, USA) unless otherwise noted.
2.2.2

Animals and Signalment
Bone marrow (BM) was collected from the sternebrae of 5 horses ranging in age from 9

months to 5 years (mean ± SD: 2.4 ± 1.7 years) and 3 pony foals ranging in age from 17 to 51
days of age. All horses were Thoroughbreds, except for one 5-year-old Quarter horse. The bone
marrow collection procedure was approved by the Institutional Animal Care and Use Committee.
2.2.3

Bone Marrow Aspiration and MSC Isolation
The methods used for bone marrow aspiration27 and MSC isolation16,19 are similar to

other reports. Briefly, young horses were selected from the research herd and after sedation with
detomidine HCl (Domosedan® 0.04 mg/kg IV). The sternebrae were aseptically prepared and
local anesthetic (2% Lidocaine, 3 ml) was infiltrated into the subcutaneous tissue. A 40-ml
volume of bone marrow aspirate was collected using a 10-gauge, 3-inch bone marrow biopsy
needles and heparinized syringes (1,000 IU/ 10ml BM aspirate). Bone marrow was also
harvested from foals by sterile curettage of the sternebrae from fresh cadavers. The marrow
trabecular bone was then crushed and gently stirred before marrow stromal cell (MSC) isolation
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and expansion, which was performed immediately after the bone marrow collection for all
animals.
The bone marrow aspirate was diluted in a 1:3 ratio with stromal medium consisting of
DMEM-Ham’s F12 medium (vol/vol, 1:1) (HyClone, Logan, UT, USA), supplemented with a
1% antibiotic/antimycotic solution (MP Biomedicals, Irvine, CA, USA) and 10% characterized
fetal bovine serum (FBS, HyClone) and layered over Ficoll-Paque® PLUS (Stem Cell
Technologies, Vancouver, BC, Canada). The nucleated cells of the BM aspirate were
fractionated over a Ficoll density gradient by centrifugation at 1400 rpm for 30 minutes at 4°C.
The MSC-enriched cell population above the Ficoll layer was then aspirated and washed in
calcium and magnesium-free Dulbecco’s balanced salt solution (CMF-DBSS) by further
centrifugation at 1,200 rpm for 5 minutes at 4°C. The washed pellet was resuspended in 10 ml of
stromal culture medium. Subsequently, a small aliquot of the cell suspension was centrifuged,
the supernatant removed and the pellet was resuspended in an equal volume of a red cell lysing
buffer for approximately 20 minutes (Sigma-Aldrich Co., St Louis, MO, USA). This extended
exposure period resulted in lysis of both erythrocytes and nucleated cells. Subsequent trypan
blue exclusion and hemocytometer counting was employed to determine the total number of
nucleated cells per unit volume of bone marrow aspirate.
2.2.4

Cell Doubling Method
Primary cells from the subjects were plated at a density of 105 nucleated cells per cm2 in

T25 culture flasks (Corning®, NY, USA) using the above described stromal culture medium.
The cells were incubated for 6 days before the first medium change, allowing MSC adherence
and facilitating removal of the nonadherent hemopoietic cell fraction. Thereafter, the medium
was changed every 3–4 days until the adherent cell population reached approximately 80%
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confluence. At this point, the adherent primary MSCs were passaged by digestion with 0.05%
trypsin, counted with a hemocytometer, and a portion of the cells were re-seeded as “Passage 1”
(P1) at 5 x 103 MSCs/cm2. For the subsequent passages (P1 to P10) cells were inoculated in T25
flasks at 5 x 103 MSCs/cm2and allowed to multiply for 3 to 4 days to approximately 70 to 80%
confluence before trypsinization and successive passage. Cell doubling times (DT) and numbers
(CD) were calculated from hemocytometer counts and cell culture time (CT) for each passage
according to the following two formulae28:
(1) CD = ln (N f N i ) ln (2 )
(2) DT = CT CD
(DT = cell doubling time; CT = cell culture time; CD = cell doubling number; Nf = final
number of cells; Ni = initial number of cells)
All primary cells of the three foals were trypsinized and cryopreserved after they had
reached approximately 80% confluence at P0. The cryopreservation medium contained 80% fetal
calf serum, 10% DMEM, and 10% dimethyl sulfoxide (DMSO. Cryovials containing the MSCs
were placed in a 5100 Cryo 1°C Freezing Container (Wessington Cryogenics, UK) for 24 hours
at -80°C before transfer to liquid nitrogen. The MSCs from the three foals, used only for cell
doubling experiments, were thawed at room temperature, counted with a hemocytometer to
assess viability, and subsequently centrifuged at 1,200 rpm for 5 minutes before resuspension in
stromal medium. The cells were then seeded for P1 at 5 x 103 cells/cm2.
The MSCs isolated from the five adult horses were used only as freshly harvested cells
that had not been cryopreserved. Cell cultures from each of the five horses were grown in
duplicate for each passage, whereas those of the three foals were only gown as single cultures.
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2.2.5

Colony Forming Unit (CFU) Assays
The CFU limit dilution assays were performed according to previously

published methods.29 A portion of the original isolated bone marrow nucleated cell pool from
the five adult horses was reserved for limit dilution assays to quantify colony forming units for
fibroblasts (CFU-F), and cells capable of differentiation into adipocytes (CFU-Ad) and
osteoblasts (CFU-Ob). Further CFU assays were performed at passage 2 (P2) and 4 (P4).
Medium exchanges were performed every two to three days. Digital images were taken with an
inverted phase contrast microscope at each passage and evaluated for cell morphology,
distribution and confluence.
Primary cells were seeded and serially diluted (2-fold) across the 12 columns of four 96well plates resulting in one plate for each CFU assay (CFU-F, CFU-Ad, CFU-Ob). Due to the
anticipated low frequency of primary MSCs in P0, the nucleated bone marrow-derived cell pool
was plated at greater per well densities relative to P2 and P4.30 Hence primary cells densities
plated in 100 μL of stromal medium per well in each column were 1 x 105, 5 x 104, 2.5 x 104,
1.25 x 104, 6.25 x 103, 3.12 x 103, 1.56 x 103, 7.8 x 102, 3.9 x 102, 1.95 x 102, 9.76 x 101 and 4.88
x 101, respectively. The cells were fed with an additional 100 μL of stromal medium after a 2 to
3 day growth period and the medium was then changed every third day. The plates were
incubated at 37 °C in a 5% CO2 humidified incubator. Cells were cultured for a total of 9 days to
establish colonies, at which time two plates were fixed as outlined below for CFU-F assays while
the cells in the two remaining plates were maintained in culture with adipocyte differentiation
media or osteogenic media for CFU-Ad or CFU-Ob assays, respectively, as described below. At
P2 and P4, the cell seeding densities for the limit dilution assays (in 96-well plates) at these two
passages were as follows: 5.0 x 103, 2.5 x 103, 1.25 x 103, 6.25 x 102, 3.13 x 102, 1.56 x 102, 7.8
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x 101, 3.9 x 101, 1.9 x 101, 0.98 x 101, 0.49 x101, 0.24 x 101. Otherwise, the limit dilution assays
were conducted as described for the primary cells.
At the conclusion of the studies, the number of wells under each cell density that were
negative for the specific marker (based on histochemical staining) was determined. Negative
staining was defined as a well that failed to contain at least 20 positive cells. These values were
then used to compute the frequency of the CFU progenitors according to the formula F = e-x,
where F is the fraction of colony negative wells, e is the natural logarithm constant 2.71, and x is
the number of colony forming units per well. Based on a Poisson distribution of a clonal cell
lineage, the value of F0 = 0.37 occurs when the number of total bone marrow-derived cells plated
in a well contains a single colony forming unit.31
2.2.6

CFU-Fibroblast (F) Assay
For CFU-F assays, cells were maintained in stromal medium for a total of 9 days.

Following incubation, the cells were rinsed twice with prewarmed PBS. The cells were then
fixed for 20 minutes in 10% formalin at room temperature and stored at 4°C until staining. The
cells were stained in 0.1% toluidine blue in 1% paraformaldehyde in PBS for 1 hour and
subsequently gently rinsed with tap water. Cells were counted using a phase contrast microscope
and the MetaVue™ Imaging System (Universal Imaging Corporation, Downingtown, PA, USA)
and aggregates of >20 toluidine blue staining cells per well were regarded as a positive CFU-F.
2.2.7

CFU-Adipogenesis (Ad) Assay
For CFU-Ad assays, cells were first cultured for 9 days in stromal medium to establish

colonies. Thereafter, the cells were exposed to an adipogenic induction medium containing
DMEM-Ham’s F12, 3% FBS, 1% antibiotic/antimycotic solution, biotin (33 μmol/L),
pantothenate (17 μmol/L), 100nM insulin (1 μmol/L), dexamethasone (1 μmol/L),
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isobutylmethylxanthine (IBMX) (0.5 mmol/L), rosiglitazone (5 μmol/L) (AvandiaTM, Glaxo
Smith Kline) and 5% rabbit serum (Invitrogen Corporation, Carlsbad, CA, USA) for 3 days.
Thereafter, the same medium without the IBMX and the AvandiaTM was used to maintain the
adipocyte cell culture until day 6 when the cells were fixed for 20 minutes in 10% formalin at
room temperature and later stained for neutral lipid accumulation with Oil Red O.32,33 The cells
were stained for 20 minutes followed by 3 rinses with distilled water. With the use of a phase
contrast microscope, cell aggregates were counted and quantified as CFU-Ad positive if the
colonies contained >20 Oil Red O positive cells.
2.2.8

CFU-Osteogenesis (Ob) Assay
For CFU-Ob assays, cells were first cultured for 9 days in stromal medium to establish

colonies. On day 9, cells were exposed to osteogenic induction medium (DMEM-Ham’s F12,
10% FBS, 1% antibiotic/antimycotic solution, β-glycerophosphate [10 mmol/L], dexamethasone
[20 nmol/L] and sodium 2-phosphate ascorbate [50 μg/ml]). Culture in the osteogenic medium
was maintained for 5 to 10 days until nodules were detected under phase contrast microscopy.
The cells were fed 3 times per week. Upon completion, the cells were rinsed 3 times with 150
mM NaCl and then fixed in 70% ethanol and stored at 4oC. A 2% Alizarin Red solution was
prepared in distilled water (pH 4.2) and the cells were stained for 10 minutes at room
temperature and thereafter rinsed 5 times with distilled water. Cell aggregates were assessed
under phase contrast microscopy for Alizarin Red staining mineralization and nodule formation.
2.2.9

Time Line of Differentiation
Primary cells of all donors were plated in 12-well-plates at 105 cells/cm2 and were

allowed to incubate for 12 days for time line differentiation experiments and observation
assessing osteogenesis and adipogenesis. To assess lineage specific differentiation, digital
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images were obtained daily from each of 6 wells containing induced cells (in adipogenic or
osteogenic media) and 6 wells containing control cells (in stromal medium). From two donors
(an 18-month-old Thoroughbred and a 5-year-old Quarter Horse), cells were induced with
adipogenic medium and cultured in four 12-well plates to day 2, 4, 6 and 10 and subsequently
fixed and stained with Oil Red O. Cells form the same two donors were also induced with
osteogenic medium and cultured in four 12-well plates. Based on our experience with human
adipose tissue-derived stem cells (ASCs)30, which require up to 3 weeks for mineralization to
occur, it was decided to examine cultures with Alizarin Red staining at day 5, 10, 15 and 20.
During the cell culture period, daily digital images were taken to monitor adipogenic and
osteogenic changes of the cells. After the cells were stained, the 12-well plates were digitally
scanned (Hewlett Packard scanner, USA) and images of the stained cells were taken from each
plate.
2.2.10 Statistics
The values are reported as the mean and standard deviation. All statistical analyses were
performed using the SAS 9.1.2 software package and the Type I error was maintained at 0.05 for
all comparisons. The cell doubling data for each passage were compared using Proc GLM and
the Tukey’s Studentized Range Test for pairwise multiple comparisons of the means. The same
mean comparisons between passages were performed for the limit dilution assay results (CFU-F,
CFU-Ad, CFU-Ob) after log transformation of the data. The modeling behavior of the MSC
doubling number from passage 0 to 10 was determined by regression analysis using Proc Reg.
2.3
2.3.1

Results
Cell Doubling Data
Ficoll separation of bone marrow aspirates collected from the adult horses resulted in the
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harvest of 6.4 ± 3.4 x 106 nucleated cells/ml of aspirate. The cell viability after thawing
the liquid nitrogen-stored primary foal MSCs was 64 ± 6%. The cell doubling time for primary
cells was calculated at 5 ± 1.6 days/cell doubling and is thereby significantly (P < 0.0001) longer
than the cell doubling time of cells in the subsequent passages (Figure 1-A). There were no
significant differences between cell doubling times of all subsequent passages, and an average
cell doubling time of 1.4 ± 0.26 days/cell doubling was calculated for passages P1-P10. There
was also no significant difference between the cell doubling data of each passage between the
foals and the population of young adult horses used for this study. By passage 10, the cells had
undergone 30 ± 2.4 cell doublings (Figure 1-B).
2.3.2

Cell Morphology Observations
The cellular morphology of primary cells included both large, widespread, and occasional

multi-nucleated cells as well as spindle-shaped, mononuclear cells. This degree of heterogeneity
decreased with subsequent passages as the smaller spindle-shaped fibroblastic cells appeared to
predominate (data not shown). Cells grown to confluence grew in multiple layers indicating a
lack of contact inhibition. In subsequent passages, the spindle-shaped fibroblastic cells detached
more readily during trypsinization, leading to a morphologically homogenous cell population.
2.3.3

Cell and Time Line Differentiation
Cell differentiation of MSCs into adipocytes and osteoblasts (Figure 2-B and 2-C) was

observed in all cultures under the appropriate conditions. A pilot study on adipogenic induction
and differentiation of equine MSCs showed that the addition of 5% rabbit serum was required for
consistent adipogenic results. After adipogenic induction, the cell morphology changed within 24
hours from the elongated confluent fibroblastic cells (Figure 3-A) to more oval-shaped cells,
which exhibit a distinct ring of dark coarse granules around the cell periphery (Figure 3-F).
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subsequeent passages.. By passagee 3 and 10, thhe equine MSCs
M
had unddergone 10.77 ± 1.5 and 30.4
3
± 2.4 celll doublings, respectivelyy. * indicatess a statisticallly significannt differencee (p < 0.00011) in
DT (A) between
b
prim
mary cells annd that of subbsequent passsages. The MSC
M doubliing number, after
log transfformation, behaved
b
in a linear fashioon (y = 1.27 + 0.255x, R2 = 0.84).
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Figure 2 – Colony Forming
F
Un
nit (CFU) Asssays and Sttaining.
The paneels display reepresentativee photomicroographs for the
t followinng colony forrming assayss:
(A) CFU
U- fibroblastss (F) detectedd by Toluidiine Blue staining (20 X magnificatio
m
on); (B) CFU
UAdipocytte (Ad) deteccted by Oil Red
R O stainiing (40 X maagnification)); and (C) CF
FU-Osteoblaast
(Ob) deteected by Alizzarin Red staining (10 X magnificattion). Bars reepresent a sccale of 100
microns.
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These granules appeared to develop into fat globules by day 2 (Figure 3-B). It was also noted
that within 6 to 10 days after induction of adipogenic differentiation these cells were more likely
to detach.
The adipogenesis time line differentiation experiment showed that lipid vacuoles became
more numerous and larger with time (Figure 3-C and 3-D). The most notably visible differences
occurred between day 0, equivalent to the cellular appearance of the control cells, and day 2
following induction.
During the limit dilution assays, osteogenesis of the equine MSCs typically occurred
within 3 to 4 days after induction. Experiments were terminated when nodules had formed at the
lowest cell dilutions within the 96-well plates, which on average occurred after 7.4 ± 2.6 days.
The osteogenesis time line experiment showed rapid mineralization and nodule formation in all
treatment wells and all plates by day 5 (Figure 4-B) for both donors’ cells. While the control
wells showed some level of Alizarin Red staining (Figure 4-A), this was minor relative to the
wells incubated under osteogenic conditions (Figure 4-B).
2.3.1

Limit Dilution Assays
Limit dilution CFU-F assays (Figure 3-A) determined that an adherent fibroblastic

phenotype occurred at a frequency of 1 per 4,224 primary nucleated BM cells (Table 1). With
subsequent passage, this population was significantly (P < 0.001) enriched; by passage 2 and 4
approximately 1 per 2.3-2.5 cells displayed an adherent fibroblastic phenotype (Table 1). CFUAd and CFU-Ob assays yielded frequencies of 1 per 7,114 adipocytes and 1 per 5,605
osteoblasts per primary nucleated BM cells, respectively. Subsequent passage significantly (P <
0.001) enriched for progenitors of both lineages. At passages 2 and 4, both lineages were
detected at frequencies of 1 per 3.6 cells or greater.
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Figure 3 – Adipogen
nesis (Time Line) and Oil
O Red O Staining.
S
Equine MSCs
M
were maintained
m
inn stromal meedium for 9 days until coonfluent. Att this time (dday
0), cells were
w induced with Adipogenic Diffeerentiation Medium
M
and maintained over a 10-daay
period. Representati
R
ve photomiccrographs (20 X magnifiication) of Oil
O Red O staained (top) and
a
unstainedd (bottom) arre displayedd for days 0, 2, 4, 6, and 10 followingg adipogenicc induction. Bars
representt a scale of 100
1 microns..
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nesis and Allizarin Red Staining.
Figure 4 – Osteogen
Equine MSCs
M
maintaained in Stroomal Medium
m for 9 days were treatedd with Contrrol (Stromal
Medium)) (A, C) or Osteogenic
O
Innductive Meedium (B, D)) for an addiitional five days.
d
Alizariin
Red stainned (A, B) an
nd unstainedd (B, D) photomicrograpphs at 20X magnification
m
n are shown.
Insets below the phottomicrograpphs display im
mages of thee entire Alizaarin Red staiined plate unnder
Control (left)
(
and Ossteogenic (rigght) conditioons. Bars reppresent a scaale of 100 miicrons.
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Table 1 – MSC Limit Dilution Assays
CFU Frequency (%)
Passage

CFU-F

CFU-Ad

CFU-Ob

P0

1:4224 ± 3265*

1:7114 ± 6657*

1:5605 ± 5266*

P2

1:2.28 ± 0.35

1:2.45 ± 0.01

1:2.45 ± 0.01

P4

1:2.54 ± 0.2

1: < 2.44

1:3.63 ± 2.37

Table 1 summarizes the frequencies (original data) of colony forming units with fibroblastic
phenotype (CFU-F), adipogenic capacity (CFU-Ad), and osteogenic capacity (CFU-Ob) within
the pool of nucleated BM cells at three different passages (P0 [n=5], P2 [n = 5] and P4 [n= 4]).
Values are expressed as the mean ± standard deviation. The number of donor animals is
indicated in parentheses. * indicates statistically significant (P < 0.001) differences from other
passages of the same CFU assay after log transformation of the data (transformed data not
shown). The CFU frequencies (> 41%) for adipocytes at passage 4 could not be accurately
calculated because of insufficient dilutions.
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2.4

Discussion
Bone marrow stromal cells are easily separated from the nonadherent hemopoietic

fraction of cells by culture and adherence to plastic dishes as early studies on human MSCs by
Friedenstein34 and Owen35 and their coworkers have shown. The colonies established in
monolayer culture are derived from a single bone marrow stromal precursor cell, the CFU-F.7,36
The current study evaluated the growth characteristics and colony forming unit frequencies of
equine MSCs. The results of this study document that plastic adherent equine bone marrowderived MSCs have a cell doubling rate of 1.4 ± 0.22 days. MSCs show an initial lag phase of
cell proliferation in primary culture, which increases in subsequent passages similar to that
documented in other mammalian species. A cell doubling time of approximately 48 hours has
been reported for dogs22 and Rhesus Macaques26. In humans, the cell doubling time of postnatal
MSCs has been reported to be approximately 24 hours.21 Surprisingly, there was no significant
difference in the cell doubling rate between foals and young horses. It is possible that a greater
number of animals in each age group would have increased the likelihood of observing a
difference in the cell doubling time between foals and young adult horses; however, it is also
plausible that there is no difference in this parameter between donors in these age categories.
Alternatively, the in vitro culture conditions employed may optimize cell growth independent of
donor age and mask any inherent differences in doubling time. Further work will be necessary to
address these questions.
Pittenger and his coworkers reported that MSC frequency in human bone marrow of between 1
per 104 to 1 per 105 nucleated cells.18 Donor age is a factor influencing human MSC frequency.
Their numbers have been reported to decline in an age-related manner from 1 in 10,000
(newborns) to 1 in 2,000,000 (an 80 year-old person).37 All of the equine donors used in the
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current study were young animals for which a higher MSC frequency would be expected.
Canine22 and feline25 bone marrow-derived MSC frequency has been reported to be 1 in 2.5 x
104 and 1 in 3.8 x 105, respectively. Our data show an equine MSC frequency among the total
nucleated BM cells of 1 in 4.2 x 103 (based on CFU-F). However, similar to a report on MSC
frequency in mice38, considerable variation for primary cell frequencies (up to ten fold) between
individual subjects was observed in our study. The current study has employed microtiter limit
dilution assays to assess CFU frequency in the bone marrow. The values obtained were within a
factor of 2 of those determined by this technique in murine bone marrow, where CFU-F/Ad/Ob
frequencies ranged between 1 in 10.8 X 103 to 1 in 3.45 X 104.29 The 1 to 2 orders of magnitude
discrepancy in the literature reports of bone marrow-derived equine, human18, canine22, feline25
and murine38 MSC frequency may be related to differences in the quantitative methods, in
addition to the age of the donor animals or some biological features unique to a particular
species. Other studies have calculated CFU frequencies by plating at densities between 103 to 105
nucleated cells per cm2 and monitoring colony formations by visual inspection after set periods
of time.25 The combination of low plating density and large culture volume may influence cell
survival relative to microtiter conditions.
Following plating and the initial plastic adherence, the low frequency of the primary CFU
populations was greatly enriched which was the reason for the reduced seeding density in the P2
and P4 analyses relative to the initial aspirate. These techniques were designed based on our
observations using adipose-derived stem cells from human fat in which subcultivation has been
found to enrich the presence of stromal cell surface markers such as CD13, CD29, CD44, CD73
and CD90 to > 90% on ASCs populations compared with < 54% of the initial primary stromal
vascular fraction cells.39
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In addition to MSC frequency, the expansion characteristics of MSCs documented as cell
doubling time and number during the early passages provide information relevant to tissue
engineering applications that will require large cell numbers, especially where scaffold seeding is
anticipated. The cell doubling time of 1.4 days/cell doubling approximates that of other species
such as humans, dogs22 and Rhesus Macaques26. However, it has been documented that the
proliferation rate and maintenance of multipotentiality of human MSCs is dependent on the cell
plating density in culture.40,41 Thus, it is important to standardize the isolation and expansion of
MSCs. In our laboratory, a routine plating density of 5 x 103 cells/cm2 was employed based on
previous studies using human adipose-derived stem cells.39 A recent report42 showed that human
bone marrow-derived MSCs (passage 3) seeded at 10 cells/cm2 expanded approximately 500fold within 12 days with a maximum cell doubling time of approximately 10 hours. When the
same cells were seeded at 1,000 cells/cm2, they expanded only 30-fold, which merely resulted in
a 5-fold greater final cell count relative to the low density plating.
Sekiya42 and his coworkers also showed significantly reduced absorbance levels for Oil
Red O after isopropyl alcohol extraction for passage 3 human MSCs that were seeded at 1,000
cell/cm2 compared with those seeded at 50 cells/cm2. Furthermore, the length of pre-incubation
(7 vs. 12 days) prior to adipogenic induction also influenced the degree of differentiation42. This
illustrates that further work will be required to optimize the seeding density and culture period to
maximize stem cell yield.
Established adipogenic differentiation protocols43 have lately been further optimized for human
bone marrow- and adipose tissue-derived MSCs. These protocols typically contain a mixture of
insulin, dexamethazone, 1-methyl-3-isobutylxanthine and indomethacin.18,43,44 More recently,
this protocol has been modified in our laboratory39 replacing indomethacin with rosiglitazone (5
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μM), which is a member of the hypoglycemic drugs, thiazolidinediones or glitazones.45 These
agents are used in humans for Type 2 diabetes due to their selective agonistic action on PPAR
gamma nuclear receptors and thereby increasing insulin sensitivity.45 The same substitution was
also adopted for the equine MSC cultures. Initial work using the same protocol as commonly
used in our laboratory39 for human adipose-derived stem cells resulted in limited adipogenesis of
the equine MSCs. Previous reports found that rabbit serum enhanced adipogenesis in vitro for
human,44,46-48 rat48 and mouse48 MSCs. Janderova et al44 showed that by using 15% rabbit serum
instead of fetal bovine serum approximately 90% of all human MSCs were Oil Red O positive
within 6 days after adipogenic induction. Our studies demonstrated that the addition of 5% rabbit
serum significantly improves adipogenesis in the equine MSCs in a comparable manner.
In conclusion, the current work documents the frequency and growth characteristics of
multipotent equine bone marrow-derived MSCs from foals and young adult horses. Based on the
CFU-F frequency of 1 in 4,224 (0.026%) within the nucleated cell pool, and an average yield of
64 million nucleated cells per 10 ml of bone marrow aspirate, it is feasible to obtain 1.664 X 104
primary MSCs. Over a 23-day culture period equivalent to 14 cell doublings, a 16,384-fold (214)
cell expansion would yield approximately 250 million progenitor cells per 10 ml of bone marrow
aspirate. Limited data are currently available concerning the number of cells required for the
repair of tendon defects and strain injuries. However, efforts to repair skeletal defects in canine
models have shown that 15 million cells/ml of implant volume were sufficient to obtain
significantly improved bone production and regeneration.49 These calculations are supported by a
study by Muschler and Midura15 who introduced a mathematical model, which calculated that 70
million osteoblasts would be required to produce a cubic centimeter of bone. Further work will
be required in the equine model to reduce these basic science discoveries to clinical practice.
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CHAPTER 3.
CHARACTERIZATION OF EQUINE ADIPOSE TISSUE–DERIVED STROMAL
CELLS: ADIPOGENIC AND OSTEOGENIC CAPACITY AND COMPARISON TO
BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS

____________________
With permission from the American College of Veterinary Surgery
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3.1

Introduction
Adult adipose tissue is a source of fibroblast-like precursor cells334-337 capable of

multipotential differentiation in a number of species. In the human literature these cells have
gained importance because they are a readily accessible in large quantities. Recent
investigations have focused on their application in the emerging field of regenerative medicine
and surgery. Whereas the nomenclature of these cells varies widely,14 the consensus reached at
the Second Annual International Fat Applied Technology Society meeting (October 3-5, 2004,
Pittsburgh, PA) was to use the acronym ‘ASC’ for adipose derived stromal cells23 or adipose
derived stem cells.24
The academic and commercial veterinary communities have paid increased attention to
stromal cells, harvested from adipose tissue (ASC) or bone marrow (MSC), as efficacious
treatment options for the debilitating and career-ending musculoskeletal injuries and diseases of
the equine athlete. The human and laboratory animal literature spanning 3 decades provides
substantial characterization of these cells and their potential application to human diseases. In
equine veterinary medicine, however, knowledge of equine stromal cells is limited and they are
currently used with the implicit assumption that their basic characteristics, such as cell doubling
time and differentiation potential, are similar to those of other species. We have recently reported
on the frequency and cell doubling characteristics for equine bone marrow-derived MSCs.338
Similar to other species, equine MSCs rapidly expanded in monolayer culture to quantities
sufficient for tissue engineering purposes and they exhibited an initial lag phase in culture.338
Expansion rates of primary cultured murine adipose tissue-derived ASCs have been reported to
be up to 5-fold faster within the first 5 - 7 days compared with primary murine MSCs.339 Once
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MSCs have stabilized in culture, their cell doubling time appears to be shorter than that of
adipose tissue-derived ASCs340 suggesting that differences exist between these 2 cell types.
Autologous ASCs are relatively quickly isolated from adipose tissue by collagenase
digestion.341 The resulting stromal vascular cell fraction (SVF) contains a greater proportion of
stromal/stem cells per unit volume relative to bone marrow. Cell yields from adipose tissue may
be influenced by age and the harvested tissue site. Because lesion size in injured tissues, such as
tendon or bone, may require large amounts of cells for therapeutic efficacy, it is advantageous to
know the cell doubling times for equine ASCs to optimize therapeutic cell harvest and
expansion. Whereas the multipotentiality and proliferative rates of equine mesenchymal stromal
cells derived from equine bone marrow57,208,338 and peripheral blood208 is documented, there is
limited literature regarding these characteristics for equine adipose-derived mesenchymal cells.
Our goal was to document the cell doubling characteristics of equine ASCs and their adipogenic
and osteogenic differentiation potential.
3.2

Materials and Methods
Subcutaneous adipose tissue was collected from the region above the dorsal gluteal

muscles of 5 horses (aged, 9 months to 5 years; mean ± SD, 2.4 ± 1.7 years). There were 4
Thoroughbred geldings (one 9- and two 18-months-olds and one 3-year-old) and a 5-year-old
Quarter horse gelding. All chemical reagents were obtained from Sigma-Aldrich (St. Louis, MO)
or Fisher Scientific International Inc (Hampton, NH) unless otherwise noted.
3.2.1

Adipose Tissue Harvest
Horses were sedated with detomidine HCl (0.04 mg/kg intravenously [IV]) and

butorphanol (0.01 mg/kg IV), the area over the dorsal gluteal muscles was aseptically prepared,
and skin and subcutaneous tissues were desensitized by local infiltration of 2% lidocaine using
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an inverted L-block. A 10–15 cm incision was made parallel and ~15 cm abaxial to the vertebral
column. Approximately 15 mL of adipose tissue were harvested over the superficial gluteal
fascia for immediate ASC isolation and the skin incision apposed with nylon suture material.
3.2.2

ASC Isolation Method
The ASC isolation procedure was based on the technique previously reported for human

ASC isolation.342 Adipose tissue was minced with a surgical blade, washed and briefly agitated
with an equal volume of phosphate buffered saline (PBS) solution to promote separation into 2
phases. The upper phase consisted of the minced and washed adipose tissue and the liquid
infranatant containing hemopoietic cells suspended in PBS was removed. The tissue was then
digested in an equal volume of a filtered (0.2 μm) PBS solution containing 1% bovine serum
albumin (BSA Type V; Sigma-Aldrich) and 0.1% of collagenase (Type I; Worthington
Biochemical, Lakewood, NJ) with continuously shaking at 37°C for ~50 minutes. Subsequently,
the sample was centrifuged at 260 g for 5 minutes. To complete stromal cell separation from
primary adipocytes the sample was briefly and vigorously agitated again and then centrifuged at
260 g for 5 minutes resulting in a stromal-vascular fraction (SFV) pellet, which contains the
nucleated cell portion of the adipose tissue harvest and therefore the ASCs.
A supernatant composed of oil, primary adipocytes and collagenase solution was
removed after centrifugation and the SVF was resuspended in 10 mL stromal medium. The SVF
is the remaining nucleated cell fraction of adipose tissue which contains the mesenchymal
stromal cells. A small aliquot of the cell suspension was centrifuged and the pellet was
resuspended in an equal volume of a red cell lysing buffer (Sigma-Aldrich) for ~20 minutes. This
extended exposure period resulted in the lysis of both erythrocytes and nucleated cells
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facilitating nuclear trypan blue staining and therefore hemocytometer assessment of total
nucleated cell numbers per unit volume of adipose tissue.
3.2.3

Cell Doubling Method
The cell doubling method and calculations described previously338 were used. Fresh

primary nucleated cells from the SVF from each of the 5 horses were cultured in duplicate for
each passage. Cells were plated in stromal culture medium at a density of 5 x 103 nucleated
cells/cm2 in T25 culture flasks (Corning®, Corning, NY). The adherent cell layer was rinsed 2
days later with warm PBS to remove any contaminating blood cells and the stromal medium was
changed every 3 days until the adherent cell population reached ~80% confluence. Adherent
primary ASCs were then passaged by digestion with 0.05% trypsin, and counted. Subsequent
passages (P1 - P10) cells were inoculated in T25 flasks at 5 x 103 ASCs/cm2 and allowed to
multiply for 4 - 5 days to ~70-80% confluence before trypsinization and successive passage.
Cell doubling times (DT) and numbers (CD) were calculated from hemocytometer counts and
cell culture time (CT) for each passage according to the following 2 formulae320:
(1) CD = ln (N f N i ) ln (2 )
(2) DT = CT CD
(DT = cell doubling time; CT = cell culture time; CD = cell doubling number; Nf = final number
of cells; Ni = initial number of cells)
3.2.4

Colony Forming Unit (CFU) Assays
CFU limit dilution assays were performed according to previous methods.97 A portion of

the original isolated SVF cell pool from the 5 horses was reserved for limit dilution assays to
quantify colony forming units for fibroblasts (CFU-F), alkaline phosphatase expressing cells
(CFU-ALP), and cells capable of adipogenic (CFU-Ad) and osteogenic (CFU-Ob)
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differentiation. The same CFU assays were performed at passage 2 (P2) and 4 (P4). Medium
exchanges were performed every 2-3 days. Digital images were taken with an inverted phase
contrast microscope (Nikon TS100F, Nikon Instruments Inc., Lewisville TX) and CoolSpot CCD
Camera (Nikon Instruments Inc) at each passage and subjectively evaluated for cell morphology,
distribution, and confluence.
Primary cells of the SVF, also referred to as passage 0 (P0), as well as cells of P2 and P4
were plated at 2-fold serial dilutions (5.0 x 103, 2.5 x 103, 1.25 x 103, 6.25 x 102, 3.13 x 102, 1.56
x 102, 7.8 x 101, 3.9 x 101, 1.9 x 101, 0.98 x 101, 0.49 x101, 0.24 x 101) across the 12 columns of
96-well plates suspended in 100 μL of stromal medium/well. In total 1 plate for each CFU assay
(CFU-F, CFU-ALP, CFU-Ad, CFU-Ob) per passage (P0, P2, P4) per animal were seeded with
cells. The plates were incubated at 37°C in a 5% CO2 humidified incubator and the medium was
changed every 2-3 days. Cells were cultured for 9 days to establish colonies, at which time the
plates were fixed as outlined below for CFU-F and CFU-ALP assays, while the cells in the 2
remaining plates were maintained in culture and induced with adipocyte differentiation media or
osteogenic media for CFU-Ad or CFU-Ob assays, respectively.
At the conclusion of the studies, the number of wells under each cell density that were
negative for the specific marker (based on histochemical staining) was determined. Negative
staining was defined as a well that failed to contain at least 20 positive cells (CFU-F, CFU-Ad)
or one bone nodule (CFU-Ob). These values were then used to compute the frequency of the
CFU progenitors according to the formula F = e-x, where F is the fraction of colony negative
wells, e is the natural logarithm constant 2.71, and x is the number of colony forming units per
well. Based on a Poisson distribution of a clonal cell lineage, the value of F0 = 0.37 occurs when
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the number of total adipose tissue-derived cells plated in a well contains a single colony forming
unit.321
All cells used for the CFU assays were initially cultured in stromal medium for a total of
9 days. The cells assigned to the CFU-F and CFU-ALP assays were fixed and stained on day 9
and those in CFU-Ad and CFU-Ob cultures were induced at that time into the intended cell line
as described below.
3.2.5

CFU-Fibroblast (F) Assay
Cells were rinsed twice with prewarmed PBS, fixed for 20 minutes in 10% formalin at

room temperature and stored at 4°C until staining. The cells were stained in 0.1% toluidine blue
in 1% paraformaldehyde in PBS for 1 hour and subsequently gently rinsed with tap water. Cells
were counted using a phase contrast microscope and the MetaVue™ Imaging System (Universal
Imaging Corporation, Downingtown, PA) and aggregates of >20 toluidine blue staining cells per
well were considered a positive CFU-F.
3.2.6

CFU-Alkaline Phosphatase (ALP) Assay
Cells were rinsed twice with prewarmed PBS, fixed in 100% ethanol and stored at 4°C

until staining. Thereafter, the cells were incubated for 1 hour in the presence of a solution
containing 5-Bromo-4-chloro-3-indolyl phosphate dipotassium/nitrotetrazolium blue chloride
(BCIP/NBT), which stains ALP positive cells purple. The plates were rinsed with water and cell
aggregates were quantified with phase contrast microscopy and regarded as CFU-ALP positive if
>20 cells stained for ALP.
3.2.7

CFU-Adipogenesis (Ad) Assay
Cells were exposed to an adipogenic induction medium containing DMEM-Ham’s F12,

3% FBS, 1% antibiotic/antimycotic solution, biotin (33 μmol/L), pantothenate (17 μmol/L),
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100nM insulin (1 μmol/L), dexamethasone (1 μmol/L), isobutylmethylxanthine (IBMX) (0.5
mmol/L), rosiglitazone (5 μmol/L) (AvandiaTM, Glaxo Smith Kline, Cidra, Puerto Rico) and 5%
rabbit serum (Invitrogen Corporation, Carlsbad, CA) for 3 days. Thereafter, the same medium
without the IBMX and the AvandiaTM was used to maintain the adipocyte cell culture until day 6
post-induction when the cells were fixed for 20 minutes in 10% formalin at room temperature
and later stained for neutral lipid accumulation with Oil Red O.322,323 The cells were stained for
20 minutes followed by 3 rinses with distilled water. Phase contrast microscopy was used to
count cell aggregates quantified as CFU-Ad positive if the colonies contained >20 Oil Red O
positive cells.
3.2.8

CFU-Osteogenesis (Ob) Assay
Cells were exposed to osteogenic induction medium (DMEM-Ham’s F12, 10% FBS, 1%

antibiotic/antimycotic solution, β-glycerophosphate [10 mmol/L], dexamethasone [20 nmol/L]
and sodium 2-phosphate ascorbate [50 μg/ml]). Culture in the osteogenic medium was
maintained for 5-10 days until nodules were detected with phase contrast microscopy and the
culture medium was changed every 3 days. Upon completion, the cells were rinsed 3 times with
150 mM NaCl and then fixed in 70% ethanol and stored at 4oC. A 2% Alizarin Red solution was
prepared in distilled water (pH 4.2) and the cells were stained for 10 minutes at room
temperature and thereafter rinsed 5 times with distilled water. Cell aggregates were assessed with
phase contrast microscopy for Alizarin Red staining mineralization and nodule formation.
3.2.9

Time Line of Differentiation
Primary cells of all donors were plated in 12-well-plates at 105 cells/cm2 and were

allowed to incubate for 12 days for time line differentiation experiments and observation
assessing osteogenesis and adipogenesis. To assess lineage specific differentiation, digital
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images were obtained daily from each of 6 wells containing induced cells (in adipogenic or
osteogenic media) and 6 control wells containing cells, which were maintained in stromal
medium in the absence of inductive factors. For the adipogenic timeline differentiation
experiment cells from 2 of 5 horses (18-month-old Thoroughbred, 5-year-old Quarter Horse)
were plated in 12-well plates, induced with adipogenic medium and cultured to day 2, 4, 6 or 10
and subsequently fixed and stained with Oil Red O. Similarly, cells from the same two donors
were prepared for osteogenesis timeline experiments and induced and cultured in osteogenic
medium. Based on our experience with human adipose tissue-derived stem cells14, which require
up to 3 weeks for mineralization to occur, it was decided to examine the osteogenic cultures with
Alizarin Red staining at day 5, 10, 15 and 20. During the cell culture period, daily digital images
were taken to monitor adipogenic and osteogenic changes of the cells. After the cells were
stained, the 12-well plates were digitally scanned (CanonScan8400F, Canon, Lake Success, NY)
and images of the stained cells were taken from each plate.
3.2.10

Statistical Analysis
Cell culture data for ASCs were compared where appropriate to those recently reported

on equine MSCs338, which were harvested at the same time from the same horses. Values are
reported as mean ± SD. All statistical analyses were performed using the SAS 9.1.2 software
package (SAS Institute Inc., Cary, NC) and the Type I error was maintained at .05 for all
comparisons.
Cell doubling data for each passage were compared using PROC GLM and the Scheffe’s
test for pairwise multiple comparisons of the means. The modeling behavior of the MSC
doubling number from passage 0 - 10 was determined by regression analysis using the PROC
REG procedure. PROC GLM and Tukey’s Studentized Range Test was used for mean
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comparisons of the limit dilution assay results (CFU-F, CFU-ALP, CFU-Ad, CFU-Ob) after log
transformation of the data.
3.3

Results
The stromal vascular fraction provided a pool of primary nucleated cells (Fig 5A). The

adherent cells presented in a mononuclear spindle-shaped form and appeared numerous and
loosely distributed across the plates within 24 hours after plating.
3.3.1

Cell Doubling Data
The adipose tissue harvest yielded 3.0 ± 1.4 x 105 nucleated cells/ml of tissue (n = 5). The

cell doubling times across 10 passages (Fig 6A) had no significant differences between all
passages and the overall mean DT across 10 passages was 2.1 ± 0.9 days/CD. By P10 the cells
had undergone 28 ± 2 CDs (Fig 6B).
3.3.2

Adipogenic and Osteogenic Differentiation and Time Line Data
During 10 days in culture, equine ASCs had robust cell differentiation into adipocytes

(Fig 7A to D) compared with non-induced cells (Fig 7E to H) in the control wells. Oil-Red-O
staining of the control cells was negative indicating that there was no visible spontaneous
adipogenesis. Successful adipogenesis required the addition of 5% rabbit serum as previously
reported for equine MSCs.338 The cell morphology of the induced ASCs changed within 24
hours, displaying a distinct ring of dark coarse granules around the cell periphery, which
developed into fat globules by day 2 after induction (Fig 5 Image C). Equine ASCs also had
consistent mineralization and alizarin red positive calcium phosphate nodule formation, which
occurred on average within 12 ± 3.8 days after induction of the ASCs.
3.3.3

Alkaline Phosphatase Expression
Alkaline phosphatase staining and expression in ASCs was compared with that in MSCs.
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ALP expression was remarkably greater in undifferentiated cells of all primary MSC cultures
and those of all subsequent passages (P2 and P4) compared with ASC cultures (Fig 8). ALP
staining was visible with the naked eye in all CFU-ALP assays on MSCs across all passages
compared with those conducted for ASCs where staining was present but detectable only with
microscopy.
3.3.5

Limit Dilution Assays

The adherent fibroblastic cell frequency in the stromal vascular fraction was 1 in 2.3 ± 0.4
primary nucleated cells as determined by the limit dilution CFU-F assays (Fig 9A). At P2 and
P4, the frequency of cells with the fibroblastic phenotype did not change significantly. CFU-Ad
and CFU-Ob assays for ASCs (Table 2) determined frequencies within the primary nucleated
stromal vascular fraction cell population of 1 adipocyte progenitor per 4.9 ± 5.4 nucleated cells
and 1 osteoblast progenitor in < 2.5 ± 0.01 nucleated cells , respectively. Even the lowest dilution
of primary nucleated cells seeded at 2.4 cells/well was not sufficient to reach the limit dilution
necessary to calculate the CFU-Ob frequency at P0, as cell expansion and osteogenic induction
still resulted in nodule formation. Subsequent passaging did not significantly enrich for
progenitors of either the adipogenic or osteogenic lineage. In the stromal vascular fraction, CFUALP assays revealed a frequency of 1 in 3.64 ± 1.29 primary nucleated cells, whereas subsequent
passages had significantly lower frequencies (P2: 1 in 97.3 ± 74.95; P4: 1 in 114.86 ± 132.61;
Table 2). CFU-ALP and CFU-Ob did show significant differences at P2 and P4. ALP expression
in bone marrow MSC cultures had frequencies for P0 of 1 in 15,035 ± 11,981, which was
significantly lower when compared with P2 (1 in 4.53 ± 4.91) and P4 (1 in < 2.44), consistent
with the frequency of CFU-F at the corresponding passages.338
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Figure 9 – Colony Forming
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Table 2 – ASC Limit Dilution Assays
CFU Frequency (%)
ASCa

a

MSCb

Passage

CFU-F

CFU-Ad

CFU-Ob

CFU-ALP

CFU-ALP

P0

1:2.3 ± 0.4

1:4.9 ± 5.4

1: < 2.44

1:3.64* ± 1.29

1:15,035† ± 11,981

P2

1:6.36 ± 3.76

1:6.52 ± 5.2

1:3.73 ± 1.48

1:97.3§ ± 74.95

1:4.53 ± 4.91

P4

1:2.54 ± 0.2

1: 4.32 ± 2.46

1:4.83 ± 5.34

1:114.86§ ± 132.61

1: <2.44

b

Adipose tissue-derived stromal cells (ASC), Bone marrow-derived stromal cells (MSC)

This table summarizes the frequencies (original data expressed as the arithmetic mean ± SD) of
adipose tissue-derived colony-forming units determined by CFU-F, CFU-ALP, CFU-Ad, and
CFU-Ob assays, as well as CFU-ALP frequency assays for bone marrow-derived colony forming
units. Donor horses = 5 for all assays.
*Indicates statistically significant (P < .001) differences from other passages of the same CFU
assay after log transformation of the data (transformed data not shown). §Statistically significant
differences (P < .001) were found for ASC cultures between CFU-ALP and the other assays
within the same passage. CFU-ALP data for MSC cultures, which have been seeded and cultured
as previously described338, are reported in this table. †Statistically significant differences (P<
.001) for MSC CFU-ALP assays were detected between P0 and the subsequent passages (P2 and
P4). Insufficient dilutions prevented CFU frequencies calculations for osteoblastic lineage
derived from ASCs at P0 and ALP expression of undifferentiated MSC at P4.
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3.4

Discussion
We designed this study to determine cell doubling times of equine adipose-derived ASCs

and to establish that these cells retain their bipotentiality with subsequent passaging. This dataset
was directly compared with equine MSCs338 because the 2 cell types were harvested and isolated
in parallel studies from the same donor horses and cultured under the same conditions.
The cell morphology of SVF cells in primary cultures appeared heterogeneous in nature, yet
compared with primary nucleated cell populations isolated from bone marrow SVF cells did not
form distinct colonies but displayed a more uniform distribution upon adhering to the culture
dish. Considerably fewer cells with a non-fibroblastic morphology were evident in the primary
ASC cultures as compared with MSC primary cultures. The fibroblastic phenotype of ASCs was
very similar to that of MSCs. ASCs did not display a lag period in their initial expansion rates as
had been observed with MSCs.338
Cell quantification of primary SVF nucleated cells in a population of middle-aged
humans with mean body mass indexes of ~24-26 are reported to vary from ~300,00014 404,000342 cells/mL of lipoaspirate, values comparable to the present equine results.342
Consistent tissue collection and laboratory techniques are pivotal for maximizing cell yields as
the number of adherent human SVF cell was found to vary significantly depending on the
collagenase digestion times, sampling size, and sampling location.343 Our equine data showed
variability in cell numbers ranging from 140,000 - 538,000 cells/mL of adipose tissue, which
may also reflect donor-dependent differences. The reason for such individual variability of
ASCs is yet unknown but it is possible that age or body mass may affect stromal cell numbers in
adipose tissue. Age has been reported to inversely correlate with human marrow-derived MSC94
yields, yet there are conflicting reports in the literature concerning human ASC yields and age.
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One study failed to demonstrate a correlation between human ASCs yields and age342. In
contrast, others observed that human stromal vascular cells showed a very significant negative
correlation between glycerol-3-phosphate dehydrogenase expression and age,344 consistent with
the conclusion that aging may diminish the number of cells capable of adipogenic differentiation.
The small population size of the horses we studied was insufficient to provide insight into the
role of age and weight as correlative variables in determining equine nucleated SVF cell yields.
Cell doubling time of ~2 days for equine ASCs was more rapid than the ~4 days required by
human ASCs14 cultured under similar conditions in our laboratory but was comparable to that of
a recently established adult murine preadipocyte cell line (2 - 2.5 days).345 This suggests that
there is some variability in ASC DT among species. This interspecies variation may be the result
of different culture conditions and medium composition.
The harvest and expansion of both ASC and MSC cells have advantages and
disadvantages. The harvest of MSCs is cosmetically more acceptable and the initial isolation
process is less involved compared with that for ASCs. However, the sternal bone marrow
collection technique commonly used with standing, sedated horses exposes them to potential
complications like pneumothorax and pneumopericardium.346,347 In addition, it places the
investigator in a precarious and vulnerable position. Whereas ASCs expand at a slightly slower
rate compared with MSCs, the significantly greater number of available primary cells makes the
ASC an interesting prospect for achieving the large cell numbers deemed necessary for tissue
engineering applications.314 Our data imply that for a 10 mL adipose tissue sample with a yield
of 300,000 nucleated SVF cells/mL of adipose tissue, the immediate available ASC number at a
frequency of 43% would be 1.3 x 106/mL. After 21 days in culture, the total ASC number would
be 1.8 x 109 cells, which is significantly greater than comparable calculations for MSCs.338
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ASC frequency in our study (43%) is ~10-fold higher than reported for humans.14 It has
been demonstrated that cell seeding density affects cell doubling rates in human MSCs31 and it is
therefore likely that this adipose-derived stromal cell type will behave similarly under different
seeding density conditions. Consequently, there is a need for optimization of seeding density and
culture period to maximize equine ASC yield.
Cell seeding density344, culture media, and additives such as thiazolidinediones329 and the
rabbit serum328 are likely to influence the rate of adipose conversion in equine ASCs. In addition,
there may be individual-dependent variation in the degree of adipogenic differentiation as it has
been previously reported for human ASCs from different donors.323 Similar to our previous
report on MSCs, the addition of rabbit serum was required to achieve any reliable adipogenesis
and fat droplet accumulation.338 Under the same conditions in the CFU assays, adipogenesis was
consistently more robust in ASC cultures compared with MSC cultures.
Differences between these 2 cell types were also noted in the time required for osteogenic
differentiation. Time from osteogenic induction based on alizarin red positive nodule formation
seen in the most diluted wells of the limit dilution assays was significantly longer for equine
ASCs (12 ± 3.8 days) compared with their MSC relatives (7.4 ± 2.6 days)338; however, equine
ASCs still appeared to produce bone nodules more rapidly than human ASCs, which required ~3
weeks.14 These results suggest that equine MSCs appear to have a greater osteogenic potential
which would be consistent with the differences seen in ALP expression between undifferentiated
ASCs and MSCs (Fig 1 Panel II). In contrast to our data, De Ugarte and coworkers348 could not
find any significant differences in osteogenic differentiation capacity between human
mesenchymal cells derived from adipose or marrow tissue. However, more recently differences
in the osteogenic potential of human MSCs and ASCs have been reported by Im et al who
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showed that ASCs expressed significantly less ALP and matrix mineralization during
osteogenesis overall as compared with MSCs.349 It is interesting that even undifferentiated
mesenchymal cells from marrow and adipose tissue show such profound differences in ALP
expression. More detailed molecular work will be required to investigate the apparent reduction
in ALP expression of undifferentiated ASCs during subsequent passaging and how that may
affect their osteogenic potential. The CFU-Ob cultures of ACSs appeared to show the same
frequencies of nodule formation, although matrix mineralization required more time. Future in
vivo studies testing osteogenic applications will be required to determine the comparative
efficacy of these 2 cell types, as ASCs may be less robust for such applications or require growth
factor supplements such as bone morphogenic proteins to achieve the MSC potential, as has
recently been described for the chondrogenic capacity of human ASCs.350
Further quantitative analysis will be required to demonstrate differences in osteogenic
and adipogenic marker expression between ASCs and MSCs. Studies in the human and murine
literature suggest that there is an inverse relationship between osteoblastogenesis and
adipogenesis.351,352 Transcriptional processes such as those mediated by the peroxisome
proliferator activated receptor gamma have been implicated.167 Ligands of this receptor are
known to activate adipogenesis and promote inhibition of osteogenesis by down-regulation of the
osteoblast transcriptional regulatory protein Cbfa-1.190 Future investigations may lead to a more
intricate knowledge of osteogenic disturbances related to delayed or non-union complications in
equine bone healing and possibly to pharmacological and/or cell-based therapeutic interventions
for such skeletal healing defects.
We concluded that equine adipose tissue-derived ASCs are capable of adipogenic and
osteogenic differentiation and display expansion characteristics similar to those reported in the
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murine literature. Equally important are the differences noted between the 2 equine stromal cell
types, the ASC and MSC, for their adipogenic and osteogenic capacity and their predifferentiation ALP expression. These findings have potential relevance to future equine
veterinary tissue engineering and regenerative medical therapies.
3.5
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CHAPTER 4.
COMPARISON OF CHONDROGENIC POTENTIAL IN EQUINE MESENCHYMAL
STROMAL CELLS DERIVED FROM ADIPOSE TISSUE AND BONE MARROW
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4.1

Introduction
The two most common types of adult equine stem cells currently used for regenerative

tissue repair are those derived from bone marrow (mesenchymal stem cells, MSC) and adipose
tissue (adipose-derived stem cells, ASC). Both cell types are readily accessible in the horse for
isolation, enrichment, and expansion. The multipotentiality of both cell types with respect to
adipogenesis and osteogenesis has been documented.1-5 While in vitro chondrogenic potential
has been described for equine MSCs, little attention has thus far been directed toward equine
ASCs. Our recent work on the osteogenic and adipogenic potential of MSCs4 and ASCs5 has
shown differences in cell frequency and in vitro growth characteristics, as well as the ability to
express alkaline phosphatase and to produce bone nodules during osteogenesis. These results
suggest inherent differences between MSCs and ASCs during adipogenesis and osteogenesis.
Studies by Im and coworkers6 in rodent models showed that ALP staining and the amount of
mineralized matrix deposition during osteogenesis was greater for MSCs compared with ASCs.
Furthermore, they reported that ASCs appeared to have reduced chondrogenic potential relative
to MSCs, based on the quantity of matrix production and cell morphology. Bone morphogenic
proteins are a subgroup of the transforming growth factor superfamily and act as signaling
factors which regulate cartilage and bone formation. Human ASCs showed reduced expression
of the bone morphogenic proteins BMP-2, -4, and -6 relative to MSCs and did not express TGFβ
receptor-1 mRNA.7 Consequently, greater concentrations of TGFβ did not enhance
chondrogenesis of ASCs and only in combination with BMP-6 did ASCs express gene profiles
similar to differentiated MSCs. It has also been reported that BMP6 enhances in vitro
chondrogenesis of MSCs.8,9 Transforming growth factor beta-1 (TGF-β1) used in combination
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with insulin like growth factor-1 (IGF-1) appears to enhance chondrogenesis in equine MSC
cultures based on proteoglycan formation and procollagen Type II mRNA synthesis.10
Based on human and rodent models, it is important to evaluate potential differences
between equine MSCs and ASCs and to establish which cells may be optimal for specific
regenerative tissue applications. The aim of this study was to compare the chondrogenic potential
of equine ASCs and MSCs pellet cultures in the presence or absence of a robust growth factor
stimulus and to establish potential differences in their extracellular matrix composition.
4.2
4.2.1

Materials and Methods
Materials
All chemical reagents were obtained from Sigma-Aldrich (St. Louis, MO) or Fisher

Scientific International Inc (Hampton, NH) unless otherwise noted.
4.2.2

Animals and Signalment
Subcutaneous adipose tissue was harvested from the region above the dorsal gluteal

muscles from 6 young Thoroughbred geldings (mean ± SD, 3.5 ± 1.1 years) and sternal bone
marrow was collected from a different group of 5 Thoroughbred geldings (mean ± SD, 4 ± 1.4
years). The procedures were approved by the Institutional Animal Care and Use Committee prior
to initiation of this study.
4.2.3

Cell Culture Studies

4.2.3.1 Bone Marrow Aspiration
The methods used for bone marrow aspiration11 and MSC isolation12,13 have been
reported. Briefly, young horses were selected from the research herd and after sedation with
detomidine HCl (Domosedan® 0.04 mg/kg IV) the sternum was aseptically prepared and local
anesthetic (2% Lidocaine, 3 ml) was infiltrated into the subcutaneous tissue. A 10-ml volume of
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bone marrow aspirate was collected into heparinized syringes (300 IU/ 10ml BM aspirate) using
a 10-gauge, 3-inch Silverman bone marrow biopsy needle. Marrow stromal cell (MSC) isolation
and expansion was performed immediately after tissue harvest.
4.2.3.2 MSC Isolation Method
Bone marrow aspirates were diluted 1:3 with stromal medium consisting of DMEMHam’s F12 medium (vol/vol, 1:1) (HyClone, Logan, UT, USA), supplemented with a 1%
antibiotic/antimycotic solution (MP Biomedicals, Irvine, CA, USA) and 10% characterized fetal
bovine serum (FBS, HyClone) and layered over Ficoll-Paque® PLUS (Stem Cell Technologies,
Vancouver, BC, Canada). Nucleated cells in the BM aspirate were fractionated over a Ficoll
density gradient by centrifugation at 1,400 rpm for 30 minutes at 4°C. The MSC-enriched cell
population above the Ficoll layer was then aspirated and washed in calcium and magnesium-free
Dulbecco’s balanced salt solution (CMF-DBSS) by further centrifugation at 260 x g for 5
minutes at 4°C. The washed pellet was then resuspended in stromal culture medium. MSCs were
expanded in primary culture (P0) to 80% confluence and then stored after cryopreservation as
described below.
4.2.3.3 Adipose Tissue Harvest
Horses were sedated with detomidine HCl (0.04 mg/kg intravenously [IV]) and
butorphanol (0.01 mg/kg IV), the area over the dorsal gluteal muscles was aseptically prepared,
and skin and subcutaneous tissues were desensitized by local infiltration of 2% lidocaine using
an inverted L-block. A 10–15 cm incision was made parallel and ~15 cm abaxial to the vertebral
column. Approximately 15 mL of adipose tissue were harvested over the superficial gluteal
fascia for ASC isolation. The skin incision was apposed with nylon suture material.
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4.2.3.4 ASC Isolation Method
The ASC isolation procedure was based on a technique previously reported for human
ASC isolation.14 Adipose tissue was minced with a surgical blade, washed and briefly agitated
with an equal volume of phosphate buffered saline (PBS) solution to promote separation into 2
phases. The upper phase consisted of the minced and washed adipose tissue. The liquid
infranatant containing hemopoietic cells suspended in PBS was discarded. The adipose tissue
was then digested in an equal volume of a filtered PBS solution containing 1% bovine serum
albumin (BSA Type V; Sigma-Aldrich) and 0.1% of collagenase (Type I; Worthington
Biochemical, Lakewood, NJ) with continuously shaking at 37°C for ~50 minutes. The sample
was centrifuged at 260 g for 5 minutes. To complete stromal cell separation from primary
adipocytes, the sample was briefly and vigorously agitated and then centrifuged at 260 g for 5
minutes. After discarding the supernatant containing oil, primary adipocytes and collagenase
solution, the stromal-vascular fraction (SFV) pellet containing the nucleated cell portion of the
adipose tissue harvest including the adipose-derived mesenchymal stromal cells (ASCs) was then
cultured in stromal medium. ASCs were expanded in primary culture (P0) and then stored after
cryopreservation as described below.
4.2.3.5 Cryopreservation of Cells
Post-thaw cell viability is reported to depend on storage concentration and hence all cells
were frozen at 0.5 million cells/ml after expansion in P0. The cryopreservation medium
contained 80% fetal calf serum, 10% DMEM, and 10% dimethyl sulfoxide (DMSO).15 Cells
were placed into a 5100 Cryo 11C Freezing Container (Wessington Cryogenics, Tyne and Wear,
UK) for 24 hours at -80°C before transfer to liquid nitrogen.
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4.2.3.6 Chondrogenesis and Pellet Cultures
For chondrogenesis experiments, primary cells (P0) were thawed and expanded (P1) to
obtain approximately 12 million cells for subsequent P2 pellet cultures (n = 30) (Table 1). Cells
were trypsinized and aliquots of 0.25 x 106 cells (P2) were placed into racked microtubes (ISC
BioExpress, Kaysville, UT) tubes and centrifuged for 5 minutes at 240 g. The resulting pellets
were then cultured and induced into chondrogenesis using DMEM/High glucose (10%), 1%
antibiotic/antifungal solution, dexamethasone (100 nM), ascorbic acid 2-phosphate (50g/ml) and
ITS+ (culture supplement containing bovine insulin, transferrin, selenous acid, linoleic acid and
bovine serum albumin [BSA]; BD Biosciences, Bedford, MA) with or without transforming
growth factor (TGFβ3) (10 ng/ml) and bone morphogenic factor (BMP6) (10 ng/ml). The 3
treatment groups were as follows: stromal medium (C), chondrogenesis medium (CH), and
chondrogenesis medium plus TGFβ3 and BMP6 (CHGF). The medium was changed every
second day in all cultures. Pellet cultures were terminated at Day 3, 7, 14 or 21 and then prepared
for compositional studies. The experimental design for the chondrogenesis study is shown in
Table 1.
4.2.4

Compositional Analysis
Pellets were either papain digested for quantification of total DNA and

glycosaminoglycans (GAG) or fixed in 10% formalin and subsequently embedded in paraffin for
staining and evaluation with light microscopy.
4.2.4.1 Histology
Multiple sections of all pellets were stained with alcian blue to evaluate proteoglycan
deposition and selected pellets sections were stained with hemotoxylin and eosin to evaluate
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pellet morphology. Representative sections of the ASC and MSC pellet cultures and their
treatment groups were read and evaluated by a pathologist (DBP).
4.2.4.2 Immunohistochemistry
Immunostaining was performed using an automated immunostainer (Dako Corp., Carpinteria,
CA). Paraffin-embedded sections were deparaffinized and rehydrated. Endogenous peroxidase
activity was quenched with H2O2 (3.0%). Slides were pretreated with proteinase K (Dako Corp.)
for antigen retrieval, blocked with horse serum (30 min) and incubated with the primary antibody
for 30 min at 25°C. Mouse monoclonal antibody (Developmental Studies Hybridoma Bank, The
University of Iowa, Iowa City, IA), reported to cross-react against equine collagen Type II16, was
diluted 1:5. After rinsing, slides were incubated with horseradish peroxidase-labeled polymer
(avidin- and biotin-free) conjugated to goat anti-mouse IgG (EnVision, Dako Corp.). Peroxidase
activity was detected using the NovaRED substrate kit (Vector Laboratories, Inc., Burlingame,
CA), and tissues were counterstained with Mayer’s hematoxylin. For each tissue, a conditioned
medium negative control, that did not contain primary antibody, was evaluated and no staining
was detected. Paraffin-embedded cartilage from the proximal third tarsus (T3) of a 3-year-old
Thoroughbred gelding was used as a positive control.
4.2.4.3 Transmission Electron Microscopy
For transmission electron microscopic (TEM) tissue examination, representative samples
taken from 3 donors of Day 21 MSC and ASC pellet cultures (C, CH, and CHGF) were used.
Paraffin-embedded pellets were deparaffinized, rehydrated with water and then fixed, processed
and embedded in an epon-araldite resin as previously reported.17 Thin sections were prepared
with an MT XL microtome (RMC Products, Tucson, Arizona), stained with uranyl acetate and
lead citrate, and observed with an electron optical microscope (JEM-1011, JEOL Ltd.,
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Table 3 – Chondrogenesis: Experimental Design
Time Course

Analyses

C

CH

CH-GF

ASC
donors

MSC
donors

Day 3

Histology/Immunohistochemistry1

1

1

1

6

5

Day 7

Histology/Immunohistochemistry
Biochemical & Pellet Size Analysis

1
2

1
2

1
2

6
6

5
5

Day 14

Histology/Immunohistochemistry
Biochemical & Pellet Size Analysis

1
2

1
2

1
2

6
6

5
5

Day 21

Histology/Immunohistochemistry

1

1

1

Biochemical & Pellet Size Analysis
Transmission Electron microscopy2

2

2

2

6
6
3

5
5
3

10

10

10

Total Pellets
1
2

Immunohictochemistry was performed on tissue from three donors for both MSC and ASC pellet cultures.
Paraffin-embedded pellets used for histology were recovered and processed for TEM.

Cell lines from a total of 5 donors were used for MSC pellet cultures and from 6 donors for ASC
pellet cultures. A total of 30 pellets per donor per cell type (MSC or ACS) were grown. Pellets
were analyzed individually for histological examination and pooled by day (2 pellets per donor)
for the biochemical analysis. Two alcian blue-stained sections per pellet for all donors were used
to measure cross-sectional pellet size. The pellets were divided into 3 treatment groups as
follows: stromal medium (C), chondrogenesis medium (CH), and chondrogenesis medium plus
TGFβ3 and BMP6 (CH-GF) and the medium was changed every third day. Pellets were
harvested at Day 3, 7, 14 and 21 in culture and then prepared for the compositional studies.

134

Lewisville, TX). Paraffin-embedded articular T3 cartilage was processed in the same manner and
used as a positive control.
4.2.4.4 Total DNA Quantification
Total DNA within the pellets was assessed with the Hoechst assay as previously
published.18 Briefly, papain digested pellet DNA concentration was assessed against a calf
thymus DNA standard curve after preparation in an assay solution (2M NaCl, 50mM sodium
monobasic phosphate, pH 7.4) containing the Hoechst 33258 dye. Pellet total DNA was
measured with a spectrophotometer (Synergy HT, Bio-Tek Instruments, Inc., Winooski, VT) and
used to normalize GAG concentrations.
4.2.4.5 Glycosaminoglycans Quantification
Pellets were digested in 100 μg/ml of papain in 0.4 mM sodium acetate (pH 6.8), 10 mM
EDTA, 200 mM l-cysteine at 60°C for approximately 24 hours. Glycosaminoglycan (GAG)
synthesis within the pellets was measured by dimethylmethylene blue (DMMB) assay as
previously described, using chondroitin sulfate C from shark cartilage as a standard.19
Cross-sectional Pellet Size – The areas of 2 different cross-sections of all alcian bluestained pellets from all donors were measured using the Image Pro Software (Cybernetics, Inc,
Bethesda, MD) after calibration with a micrometer.
4.2.5

Statistical Analysis
The study design employed a repeated measures analysis of variance in a split plot

arrangement of treatments. The main plot was arranged as a 2 by 3 factorial including 2 cell
types (MSC, ASC), three treatments (C, CH, CHGF) and the cell type by treatment interactions.
The error term used for the main plot was donor within cell type by treatment. The subplot
factors included day, day by cell, day by treatment and day by cell by treatment interactions.
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Tukey’s test was employed for post-hoc main effect comparisons and the T test was used for
pair-wise comparisons of the least square means to examine the interaction effects. All statistical
analyses were performed using the Proc GLM procedure of the SAS 9.1.2 software package
(SAS Institute Inc., Cary, NC) and the Type I error was maintained at α = .05 for all
comparisons. Data are presented as the arithmetic mean ± standard error in all figures.
4.3
4.3.1

Results
H&E and Alcian Blue Histology
Histological examination of pellets stained with H&E showed that those cultured from

MSCs produced a hyaline cartilage-like morphology by Day 14 (Fig. 10) based on characteristic
lacunae formation containing round chondrocytes typically associated with maintenance of
chondrogenesis.20 Pellets grown from ASCs maintained an immature fibroblastic tissue
appearance for the duration of the study. MSC pellets showed consistently more intense
proteoglycan staining than ASC pellets (Fig. 11). Mild alcian blue staining was notable as early
as Day 3 in MSC pellets treated with growth factors, but was not apparent in ASCs until Day 14.
Under chondrogenic conditions without added growth factors, proteoglycan staining was less
intense for both cell types but MSC differentiated pellets showed proteoglycan staining by Day
7, which was a week earlier than for ASCs.
ASCs under chondrogenic conditions without growth factors pellets showed fibrillar
matrix by Day 7. The outer pellet layers were often composed of cohesive and spindeloid cells
arranged parallel to the surface varying in thickness from 3 to 10 cells. Inner layers tended to
palisade and were variably arranged perpendicular to the surface. Under growth factor treatment
the matrix density of the outer cell layer was increased at Day 14. Pellets showed a broad
external zone of spindeloid cells arranged parallel to the surface approximately 150 to 200 µ

136

Figure 10: Hematoxylin and Eosin (H&E) Staining of ASC and MSC Pellets
The figure shows that pellets cultured from both cell types showed an initial peripheral layer
formation and maturation by Day 14 in form of a deeper palasading and perpendicular
arrangement of cells. However, only MSC-grown pellets produced hyaline cartilage by Day 14.
The appearance of these pellets showed the characteristic lacunae formation containing
chondrocytes. Pellets grown from ASCs never showed evidence of hyaline cartilage formation
but rather maintained the immature fibroblastic tissue appearance.

137

Figure 11: Alcian Blue Staining of ASC and MSC Pellet Cultures
Pellets cultured from MSCs showed consistently more intense staining than those cultured from
ASCs. Mild proteoglycan staining was notable as early as Day 3 in MSC pellets treated with
BMP6 and TGFβ3 but was not notable in ASCs until Day 14 under the same conditions.
Chondrogenic conditions without added growth factors led to less intense proteoglycan staining
for both cell types but MSC differentiated pellets showed proteoglycan staining by Day 7, which
was a week earlier than was seen for ASCs. The ASC-CH and ASC-CHGF pellets of Day 14
pellet show evidence of an edge artifact.
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in thickness. By Day 21 only one of the ASC pellets showed moderate amounts of dense hyaline
extracellular matrix, which was not birefringent. Moderate alcian blue staining of extracellular
matrix by Day 14 suggests proteoglycan expression in the stroma.
MSC pellets without growth factor treatment developed several layers of spindle cells
arranged parallel to the surface by Day 3. Palisading spindle cells were arranged perpendicular to
the surface. No extracellular matrix was seen, yet mild alcian blue staining was noted in the
peripheral zone in CHGF MSC pellets. Within 4 days the outer zone showed spindle cells layers
vary from 3 to 10 cells in thickness arranged parallel to the surface surrounded by moderate
fibrillar extracellular matrix. There was no alcian blue staining of the outer zone of Day 7 MSCs
pellets but moderate staining of the matrix in the deeper layers. Partial chondroid differentiation
was noted, characterized by abundant extracellular matrix with round to stellate cells, often
located within the lacunae and organized into rows perpendicular to the surface. Intense alcian
blue staining was seen in the deeper cartilaginous appearing zone by Day 14 and the bulk of the
pellet showed prominent chondroid differentiation. The matrix was eosinophilic near the surface
but the thick chondroid differentiated zone appeared hyaline-like, typical of cartilaginous matrix
and was only very mildly birefringent. Cells were round to oval and positioned within lacunae.
Day 21 MSC pellets had a similar appearance but much of the matrix was birefringent under
polarized light suggesting some collagen type I deposition as hyaline cartilage is usually not
bifringent. There was evidence of variable central necrosis in most pellets of both cell types by
Day 14.
4.3.2

Collagen Type II Immunohistochemistry

Collagen type II expression was noted by Day 7 in MSC pellets cultured with BMP6 and TGFβ3
(Fig. 12). No evidence of collagen staining was observed in ASCs under the same conditions.
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Figure 12: Collagen Type II Immunohistochemistry of ASC and MSC Pellets
The figure shows convincing Collagen Type II expression in MSC pellets when cultured with
BMP6 and TGFβ3. ASC pellets did not show any evidence of collagen staining under the same
conditions and are therefore not shown. Pellet cultures under chondrogenic conditions without
growth factors showed mild staining by Day 14 whereas ASC pellets again did not express
antigen for the collagen Type II antibody. All pellets were exposed to conditioned medium
serving as negative control for unspecific staining and mature cartilage from the proximal
surface of the third tarsus (T3) was used as positive control (data not shown).
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MSC pellet cultures under chondrogenic conditions without growth factors showed mild staining
by Day 14 whereas ASC pellets again did not express collagen type II. The positive controls of
paraffin-embedded cartilage sections stained less intensely for collagen Type II than the pellets,
presumably because the cartilage sections had previously been decalcified, a process that is
thought to have affected the cartilage epitopes and therefore affecting antibody binding affinity.
4.3.3

Transmission Electron Microscopy
ASC pellets (CH and CHGF treated) from only one of three donors developed any

appreciable amounts of collagen fibrils, whereas all examined MSC pellets (CH and CHGF; n =
3 donors) showed abundant collagen fibrils. MSC pellet cultures formed more fibrils and had
more cohesive areas of extracellular matrix compared to ASC pellets. Collagen fibrils were
virtually undetectable in the control (C) cultures. It was notable that pellets showed a random
arrangement of fibrils similar to the transitional cartilage zone of articular cartilage (Fig. 13-E).
Areas of linear fibril arrangement were seen in pellet cultures of both cell types but it was not
possible to determine from which pellet layers they originated. MSC pellets (Fig. 13-D) appeared
to have thinner collagen fibrils compared with articular cartilage (Fig 13-E) as well as less
interfibrillar extracellular matrix. However, compared with ASC pellets (Fig. 13-B) MSC fibrils
seemed thicker and more mature.
No compositional differences were discernable under TEM evaluation between CH and
CHGF treatments.
4.3.4

DNA Concentration
DNA concentrations (Fig. 14) were significantly lower in control pellet cultures

compared to those treated chondrogenic media with and without BMP6 and TGFβ3 for both
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Figure 13: Transmission Electron Microscopy
Sections of ASC cultures (CHGF) shown in panel A and B clearly show collagen fibrils at 40k
and 80k magnification, respectively. Panel C and D represent MSC pellets (CHGF) which had a
similarly random fibril arrangement as the image of the transitional zone of equine articular
cartilage (panel E, 40K magnification) but showing less interfibrillar extracellular matrix. Panel
D (MSC pellet at 80K magnification) shows more mature and thicker fibril structure compared to
that of ASC pellets (panel B, 80K magnification) but MSC fibrils still appear to have a smaller
diameter compared with articular cartilage fibrils (Panel F, 80K magnification).
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ASCs and MSCs (P < .0001) on Day 7. Significantly lower DNA concentrations were also seen
for control cultures (P < 0.009) compared to chondrogenic cultures with and without growth
factors on Day 14 (P < .0001) and 21 (P < .0001) compared to Day 7. The only other significant
difference found was for control and CH ASC cultures on Day 21 (P = .02).
4.3.5

GAG Concentration
GAG concentrations (Fig. 15) normalized to total DNA concentrations were not

significantly different for any cultures at Day 7. On Day 14, MSCs treated with growth factors
showed significantly greater GAG concentrations than all other treatments for both cell types (P
< .0001). On Day 21 MSCs cultured under chondrogenic conditions with and without growth
factors expressed higher GAG concentrations compared with ASCs grown under the same
conditions (ASC-CH vs. MSC-CH, P = .0044; ASC-CHGF vs. MSC-CH, P = .0076; ASCCHGF vs. MSC-CHGF, P < .0001).
4.3.6

Pellet Cross-sectional Measurements

Cross-sectional pellet size of ASC-derived pellets (Fig. 16) did not vary in any of the treatments,
with the exception of CH between Day 3 and 21 (P = .0062). Pellet sizes grown from CHGFtreated MSCs were significantly larger than CH-treated pellets on Days 14 (P = .0032) and Day
21 (P < .0001). Significant differences in CHGF treatments were found between Days 3 and 7
(P=.05), approaching significance between Days 3 and 14 (P = .058) and Day 21 was
significantly different from Day 3 (P < .0001), 7 (P = .005) and 14 (P = .0043). CH-treated MSC
pellets were larger than ASC pellets grown under the same conditions on Day 7 (P=.013).
However, MSC pellets were larger compared to ASC pellets on Days 7 (P = .0078), 14 (P <
.0001) and 21 (P < .0001) after culture under CHGF conditions. After Day 7 MSC pellet size of
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Figure 14: Total DNA Concentrations
ASC pellet cultures of days 7, 14 and 21 and MSC Pellets cultures of days 7 and 14 grown under
chondrogenic conditions (± growth factors) had significantly greater total DNA concentrations
compared to their control cultures (P < .0001). The data are represented as the arithmetic mean ±
SE (ASC cultures, n=6; MSC cultures, n=5).
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Figure 15: Total Glycosaminglycan Concentrations
Relative DNA corrected GAG concentrations were not significantly different for any cultures on
Day 7. By Day 14 significant differences were seen between MSCs treated with growth factors
and all other treatments for both cell types (P < .0001). A week later MSCs cultured under
chondrogenic conditions with and without growth factors showed significant differences to
ASCs grown under the same conditions (ASC-CH vs. MSC-CH, P = .0044; ASC-CHGF vs.
MSC-CH, P = .0076; ASC-CHGF vs. MSC-CHGF, P < .0001). The data are represented as the
arithmetic mean ± SE (ASC cultures, n=6; MSC cultures, n=5).
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Figure 16: Pellet Cross-sectional Measurements
ASC-derived pellet cultures grown with or without growth factors showed no differences in
cross-sectional pellet areas. Pellet sizes grown from MSCs were significantly different between
CH and CHGF treatments on Days 14 (P = .0032) and Day 21 (P < .0001). On Day 7 significant
differences were seen in CHGF treated ASC and MSC pellets (P < .0078). Day 21 MSC pellets
treated with growth factor (CHGF) were significantly different from those of Days 3 (P < .0001),
7 (P = .005) and 14 (P = .0043). The comparison of CH treatments between MSC and ASC
grown pellets showed significant changes only on Day 7 (P=.013). However, comparing CHGF
treatments between the two cell types showed differences on Days 7 (P = .0078), 14 (P < .0001)
and 21 (P < .0001). Cross-sectional areas of pellets grown in stromal medium (C) were not
measured due to the lack of characteristic pellet structure. The data are represented as the
arithmetic mean ± SE (ASC cultures, n=6; MSC cultures, n=5).
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CH treated cultures decreased significantly (P = .016). A trend in decreasing pellet size was also
noted for ASCs but was not significant. Pellet sizes were not assessed for control cultures
because the lack of structural integrity caused a progressive loss of cell material in time despite
careful media changes. The correlation between GAG corrected for DNA and pellet crosssectional area approached significance at a p value of 0.076.
4.4

Discussion
The use of stem cells in equine veterinary medicine is beginning to expand to

applications beyond tendon and ligament repair. MSCs injected directly into joints has
significantly contributed to the healing process of experimentally induced meniscal lesions in
sheep, rats and dogs.21-25 The application of stem cells in the traumatized and osteoarthritic
equine joint was debated at the recent 2007 Symposium of the American College of Veterinary
Surgeons debated. Results of a clinical study presented at this meeting showed that 10 out 15
horses suffering from a variety of joint related pathologies with poor prognosis recovered and
returned to work after cell-based therapy with MSCs.26 It was suggested that MSCs are
beneficial to articular cartilage recovery as long as the joint surface was not denuded of cartilage
with evidence of subchondral bone exposure. Furthermore, it was postulated that gene-modified
MSCs may provide more significant results.26
The in vitro chondrogenic potential of equine MSCs has previously been documented in
monolayer cultures10,13,27, three-dimensional fibrin disks10, and pellet cultures.2,3,28,29 In a recent
study, Kisiday and his coworkers compared chondrogenesis in equine adipose tissue and bone
marrow-derived progenitor cells.16 The mesenchymal stromal cells were cultured in agarose and
self-assembling peptide hydrogels with or without the transforming growth factor TGFβ1.16 The
results of this study were consistent with our data, demonstrating the superiority of bone marrow
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MSCs in their chondrogenic potential. Similar to our study, equine ASCs demonstrated the
ability to synthesize extracellular matrix in the form of proteoglycans and glycosaminoglycans,
yet unlike bone marrow MSCs, the adipose tissue–derived progenitor cells did not demonstrate
any collagen Type II expression during the 3 week culture period. However, ASCs responded to
TGFβ1 treatment with elevated levels of hydroxyproline and glycosaminoglycan production in
peptide hydrogel cultures.16 These results suggest that equine ASCs express receptors to TGFβ1
or at least may respond to the growth factor through alternate pathways.
The differences in the chondrogenic potential between the two equine cell types are
consistent with studies on human and rodent adipose and marrow-derived mesenchymal
progenitor cells.6,30-32 However, Hennig32 and coworkers recently showed that human ASCs do
not express significant levels of TGFβ receptor-I mRNA, suggesting that human ASCs do not
have receptors for TGFβ1. Human ASCs did not respond significantly to culture supplementation
of TGFβ1 at 10ng/ml or higher concentrations, levels comparable to those used in both in
Kisiday’s and our current study. However, endoglin (CD105), a component of the TGFβ type I
and II receptor complex33, was expressed on both human ASCs34 and MSCs35 as part of their
surface marker profile. Reports have suggested that dexamethasone36 in chondrogenic protocols
may suppress any stimulatory effects of TGFβ1 and this may contribute to the observed tissuedependent differences between MSCs.
The growth factor TGFβ3 enhances chondrogenesis due to its putative role in the
regulation of cell adhesion molecules, cytokines, and cytokine receptor synthesis.37-39 Estes and
his coworkers have shown that BMP6 and TGFβ3 controlled chondrogenic induction in human
ASC-derived alginate bead cultures and increased collagen Type II (COL2A1) by 38-fold and
42-fold, individually, and by 56-fold when used in combination,.40 Also TGFβ3 had significant
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effects on collagen type X (COL10A1), suggesting a role in hypertrophic collagen synthesis.
Recent work41 on MSCs derived from equine umbilical cord blood (UCB), reported that TGFβ3
stimulated chondrogenesis; however, necessary controls were not presented to allow assessment
of the relative influence of this growth factor on the chondrogenic potential.
Consistent with Estes et al40 but in contrast to our own findings in the equine model,
Hennig32 and coworkers found that the addition of BMP6 resulted in similar chondrogenic
induction of human ASCs and MSCs. If the work by Awad36 and coworkers on human ASCs is
extrapolated to the equine ASC model, then the relatively higher concentration of
dexamethasone in our study (100nM) compared to Hennig’s study (20nM) may have inhibited
chondrogenic differentiation and accounted for the dimished ASC response compared to bone
marrow MSCs. Regardless, our results indicate that there are inherent differences between these
two equine cell types. Receptor profiles of ASCs may differ between these progenitor cells of
different species. Further investigations will be necessary to determine whether the cytokine
receptor profiles of equine ASCs and bone marrow MSCs differ and if this could account for
their differential chondrogenic responses.
The immunohistochemical staining of collagen type II in MSC pellets demonstrated a
pattern whereby signal was apparent within the zone below the superficial spindeloid cells layers
and faded toward the center of the pellet. This pattern may be related to oxygen diffusion and
may reflect the location of an oxygen tension gradient particularly suitable for chondrocytic
synthesis of collagen type II fibrils. It is known that articular cartilage in vivo is bathed in joint
fluid with a relatively low oxygen concentration (~ 5%).42 Proliferation of human adipose tissuederived stem cells is inhibited at oxygen tension of 5% but the rate of protein synthesis increases
by 2-fold and that of collagen synthesis by 3-fold and glycosaminoglycan synthesis and lactate
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production are increased as well.42 Also, both cartilage thickness and cell density affect oxygen
tension of in vitro cartilage sections43 and oxygen tension has been associated with the regulation
of chondrogenic induction and a concomitant decrease in cell proliferation.20 Thus, oxygen
tension may play a role in the current study and merits further investigation.
The pellet morphology of equine ASC and MSC cultures showed considerable
differences. Of note was the significant reduction of MSC pellet sizes under chondrogenic (CH)
conditions during the second week in culture. Human chondrocytes44 and mesenchymal stem
cells45 express the contractile protein, α-smooth muscle actin (SMA), which is believed to cause
in vitro pellet formation46 after chondrogenic induction and is essential to cell-mediated
contraction leading to tissue remodeling and collagen synthesis. Scaffold designs with variable
resistance to cell-mediated contraction have been used to show that chondrocytic cell phenotype
and collagen type II synthesis was superior in scaffolds permissive to contraction.47 Tissue
remodeling, contraction and cartilage synthesis is enhanced by treating canine chondrocytes
seeded onto collagen type II-GAG scaffolds with fibroblast growth-factor-2 (FGF-2).48 FGF-2
has also recently been shown to enhance chondrogenesis in equine mesenchymal stem cells due
to an anabolic effect on glycosaminoglycan content and collagen type II expression.29 Consistent
with these reports, the smaller pellet size seen in MSC chondrogenic cultures on Day 14 in this
study coincided with the appearance of hyaline-like cartilaginous tissue shown in Figure 1. ASC
pellets, however, showed a similar but non-significant trend in size reduction suggesting some
degree of tissue remodeling consistent with the glycosaminoglycan deposition and the traces of
collagen type II synthesis observed using TEM. In contrast the increased size of MSC pellets
stimulated by BMP6 and TGFβ3 was quite striking, which appeared to obscure the contractile
effect on pellet matrix remodeling during chondrogenesis and warrants further investigation.
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The lack of the characteristic structure of pellets grown in stromal medium (C) prevented
the measurement of their cross-sectional area. Failure to form a sufficiently robust extracellular
matrix rendered the control pellets susceptible to cell loss during media changes. Only a few
cultures in the control medium (C) formed pellets that remained intact for the duration the study;
of these, most were derived from MSCs. The cellular loss in the control cultures due to media
change is believed to account for the reduction in DNA content seen on Day 7 in control pellets.
The ~three-fold reduction in total DNA content evident in CH and CHGF cultures after Day 7
was attributed to the progressive central necrosis in pellets of both cell types. The lack of
differences among the normalized GAG concentrations between controls and the treated pellet
cultures it thought to relate to relative differences in DNA and measured GAG concentrations
between control cultures and treated cultures. Additional variation in the data may be due to the
fact that MSCs and ASCs were isolated from two different populations of horses.
In summary, our data show that equine bone marrow derived MSCs exhibited superior
chondrogenic potential compared to ASCs in the presence of stimulatory growth factors.
Nevertheless, the easy access to ASCs in the horse makes these cells an attractive choice for
tissue engineering purposes. Further investigations of receptor profiles of equine ASCs and
MSCs are needed in order to optimize cell selection for the purpose of regenerative tissue repair
and cartilage resurfacing in the horse.
4.5
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CHAPTER 5.
CONCLUSIONS AND FUTURE DIRECTIONS
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The significance of these studies is that stem cells from equine bone marrow and adipose
tissue can be reliably harvested, isolated and expanded to large numbers in relatively short
periods. In vitro cell growth characteristics and differentiation multipotential provides a basis for
the study of these cells in association with scaffold materials and cell-based therapeutic
techniques. The data demonstrate that there are differences between the two cell types with
respect to cell growth, cell marker expression and their differentiation potential, which will
require further investigation to optimize culture conditions and determine receptor profiles to
maximize their use for tissue engineering purposes.
Our studies have shown that MSCs and ASCs occur more frequently in bone marrow and
adipose tissue compared with other species. However, the frequency data is quite variable and
the population size was limited making it difficult to predict cell frequencies accurately. Both
cell types exhibited robust adipogenesis and osteogenesis; however, osteogenesis occurred more
rapidly in MSCs compared to ASCs. Undifferentiated MSCs expressed more ALP than ASCs,
which would support the notion that MSCs are better equipped for osteogenesis compared with
ASCs. Likewise, adipogenesis appeared more robust in ASC cultures compared with MSC
cultures. These observations will require further molecular assessment but are consistent with the
natural environment of these two cell types. Similar to other species both MSCs and ASCs
maintained differentiation potential during later passages.
MSCs showed superior chondrogenic potential based on histological morphology,
collagen type II immunohistochemistry and proteoglycan expression. Pellet morphology of
MSCs was much more reminiscent of hyaline cartilage than the matrix organization of pellets
grown from ASCs. Proteoglycan expression in ASC pellets compared with the controls suggests
that these cells do respond to chondrogenic culture media and that BMP6 and TGFβ3 have an
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additional positive affect on ASC differentiation and pellet maturation. However, the lack of
collagen Type II expression and the morphological immaturity of ASC pellets suggest that ASCs
may require different culture conditions and/or additional stimuli to perform similarly as MSCs.
Under the present conditions the bone marrow derived stromal cells clearly show superior
chondrogenesis as early as Day 7. Receptor expression profiles will need to be studied in the
future to elucidate culture requirements for these two cell types to optimize the use of ASCs and
MSC in tissue engineering. The high cell numbers that could easily be harvested in horses makes
these cells a potential source of cell for regenerative tissue repair purposes. Future studies will be
directed at optimization of their use in tissue engineering.
Our research efforts thus far, using equine stem cells have mostly concentrated on
characterizing the in vitro growth and differentiation properties of these cells and we have also
employed these cells clinically in studies on equine tendonitis. Because we can reliably generate
large numbers of cells we have established the ground work for additional studies on optimizing
culture conditions and on the effect of appropriate bioabsorbable scaffolds, cellular geneenhancement and mechanoinduction prior to implantation, which may all play an important role
in enhancing the potential of equine bone marrow and adipose tissue derived stem cells for their
use in regenerative tissue repair.
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